-
Notifications
You must be signed in to change notification settings - Fork 0
/
combined2.csv
We can't make this file beautiful and searchable because it's too large.
3781 lines (3781 loc) · 949 KB
/
combined2.csv
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
nct_id,overall_status,start_date,completion_date,condition,Study design info,eligibility,has_expanded_access,enrollment
NCT04453566,Recruiting,"May 27, 2020",December 2020,"COVID-19,Life Satisfaction,Anxiety,Mental Health Wellness 1,Athlete,Stress","Other,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:35 Years",No,120
NCT04403386,Recruiting,"June 1, 2020","May 31, 2022",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:30 Years,Max Age:55 Years",No,200
NCT04526977,Not yet recruiting,"September 1, 2020","September 30, 2021","Covid19,Immune Suppression,HIV-1-infection","Case-Control,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:85 Years",No,90
NCT04561102,Enrolling by invitation,"September 11, 2020","December 31, 2020",SARS-CoV-2,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2500
NCT04375735,Not yet recruiting,"July 1, 2020","July 1, 2021","ARDS, Human,COVID-19","Randomized,Parallel Assignment,Patients will be randomly assigned to either receive exogenous surfactant daily for 3 days, or receive standard treatment.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04320472,Recruiting,"March 23, 2020",December 2020,"COVID-19,Encephalopathy,Critically Ill","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,250
NCT04508023,Recruiting,"August 13, 2020","April 6, 2021",Coronavirus Disease 2019 (COVID-19),"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04460027,Recruiting,"June 22, 2020","August 31, 2020","Substance Use Disorders,Alcohol Use Disorder","Randomized,Parallel Assignment,Treatment,Double (Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:65 Years",No,160
NCT04349540,"Active, not recruiting","April 15, 2020","January 15, 2021",COVID19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:3 Months,Max Age:N/A",No,40
NCT04323527,Completed,"March 23, 2020","June 7, 2020","SARS-CoV Infection,Severe Acute Respiratory Syndrome (SARS) Pneumonia","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,278
NCT04506528,Recruiting,"August 10, 2020","December 31, 2021","Covid19,Cancer,Nicotine Dependence,Pulmonary Disease,Cardiovascular Diseases,Immunosuppression Disorders","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,170000
NCT04568525,Completed,"July 1, 2020","August 1, 2020",Covid19,"Randomized,Parallel Assignment,Randomized clinical trials,Diagnostic,Single (Participant)","gender:All,Min Age:18 Years,Max Age:75 Years",No,195
NCT04407507,Not yet recruiting,June 2020,October 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Care Provider)","gender:All,Min Age:18 Years,Max Age:N/A",No,66
NCT04517136,Recruiting,"September 14, 2020","February 14, 2021","Covid19,SARS-CoV Infection,Burnout, Caregiver,Burnout, Professional","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:60 Years",No,60
NCT04361019,Recruiting,"April 16, 2020","October 20, 2020",Physical Activity,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,25000
NCT04385251,Recruiting,"June 18, 2020","June 30, 2021","COVID,COVID19,SARS-CoV 2,Dyspnea","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,10000
NCT04339816,Recruiting,"May 13, 2020","June 30, 2022","COVID-19,Respiratory Failure","Randomized,Parallel Assignment,Prospective, multi-centre, randomised, pragmatic, double blind trial,Treatment,Triple (Participant, Care Provider, Outcomes Assessor),Visually unrecognisable IP or placebo will be prepared by dedicated unblinded study pharmacist and handed over to care provider immediately before administration","gender:All,Min Age:18 Years,Max Age:N/A",No,240
NCT04344756,Not yet recruiting,"April 20, 2020","September 30, 2020",COVID19 Pneumonia,"Randomized,Parallel Assignment,Randomized clinical trial with 2 parallels arms, 1:1, stratified on disease severity (ventilation or not),Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,808
NCT04377997,Not yet recruiting,"May 15, 2020","January 1, 2022","Cardiovascular Diseases,COVID-19","Randomized,Parallel Assignment,randomized 1:1,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04391127,"Active, not recruiting","May 4, 2020","September 30, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Care Provider),Two non-transparent bottles The first bottle will contain the initial treatment: Two ivermectin tablets, two hydroxychloroquine tablets, or two placebo tablets.
The second bottle will contain the follow-up treatment (10 tablets): Two tablets will be indicated, which will be take 12 hours after ingestion of the initial bottle and then one tablet every 12 hours for 4 more days. This bottle will contain placebo and hydroxychloroquine according to the corresponding group.","gender:All,Min Age:16 Years,Max Age:90 Years",No,108
NCT04324190,Recruiting,"April 8, 2020",December 2021,"COVID-19,Psychosocial Stress,Mental Health","Randomized,Sequential Assignment,Randomized controlled trial with a waiting comparator condition (provision of WHO recommendations, comparable to treatment as usual, TAU), consisting of a two weeks waiting period during which general WHO recommendations how to handle stress in the context of the COVID-19 pandemic will be provided. All subjects in the waiting condition will undergo the intervention following the waiting period. Main assessments will be conducted before the waiting period, before beginning of the intervention, two weeks after beginning of the intervention (+2 weeks), +4 weeks, +12 weeks, and follow ups at +6 months and +12 months.,Treatment,Single (Care Provider),Care providers (providing guidance) are not informed about wether participants have been assigned to the online support program condition or the comparator condition, consisting of a waiting period followed by the online support program.","gender:All,Min Age:18 Years,Max Age:N/A",No,600
NCT04499677,Recruiting,"September 24, 2020","March 1, 2021",COVID-19,"Randomized,Factorial Assignment,Randomised, double-blind, 2x2 factorial placebo-controlled,Treatment,Triple (Participant, Care Provider, Investigator),Double-blind","gender:All,Min Age:18 Years,Max Age:70 Years",No,240
NCT04466306,Enrolling by invitation,"April 15, 2020","July 1, 2021","Acute Kidney Injury,COVID","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:25 Years",No,250
NCT04413955,Recruiting,"June 1, 2020","December 31, 2021","COVID-19,SARS-CoV 2","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04575168,Not yet recruiting,October 2020,November 2020,Covid19,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04396353,"Active, not recruiting","June 4, 2020","January 20, 2021","COVID-19,SARS-CoV 2,Corona Virus Infection,Sedentary Behavior","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1574
NCT04368728,Recruiting,"April 29, 2020","December 11, 2022","SARS-CoV-2 Infection,COVID-19","Randomized,Parallel Assignment,Prevention,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:16 Years,Max Age:N/A",No,43998
NCT04371302,Not yet recruiting,"May 1, 2020","June 30, 2020","Burnout, Professional,Medical Errors,Depression","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,145
NCT04487886,Not yet recruiting,August 2020,February 2022,COVID-19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Care Provider)","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04323631,Withdrawn,"April 30, 2020","April 30, 2020",COVID-19,"Randomized,Sequential Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04358029,Recruiting,"April 9, 2020",December 2021,"COVID 19 Cardiac,COVID 16 Arrhythmia,COVID 19 Death","Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,10000
NCT04343664,Not yet recruiting,"August 1, 2020","December 31, 2020","Mental Stress,Mental Health Wellness 1,Depression,Anxiety,Behavior Problem,Emotional Problem","Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:4 Years,Max Age:N/A",No,10000
NCT04508712,Not yet recruiting,"August 10, 2020","August 31, 2021",COVID-19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,900
NCT04444271,Recruiting,"May 1, 2020","September 30, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:10 Years,Max Age:N/A",No,20
NCT04362956,Recruiting,"July 10, 2020","September 30, 2020","Covid19,Pregnancy Related,Neonatal Infection","Case-Control,Prospective","sampling_method:Probability Sample,gender:Female,Min Age:N/A,Max Age:N/A",No,200
NCT04379245,Completed,"April 30, 2020","May 4, 2020","HIV,Pre-exposure Prophylaxis","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,4200
NCT04386616,Recruiting,"June 2, 2020","March 3, 2021",COVID-19 Pneumonia,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,390
NCT04456426,Not yet recruiting,July 2020,August 2020,"COVID,SARS-CoV 2,SARS Pneumonia,SARS (Disease),SARS (Severe Acute Respiratory Syndrome)","Ecologic or Community,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:120 Years",No,250
NCT04345679,Not yet recruiting,"April 14, 2020","April 1, 2021",COVID 19,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04335279,Completed,"April 9, 2020","July 24, 2020","Scleroderma,Scleroderma, Systemic,Systemic Sclerosis","Randomized,Parallel Assignment,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,172
NCT04343989,Recruiting,"March 31, 2020","July 1, 2020",COVID-19,"Randomized,Parallel Assignment,This is a randomized, double-blind, placebo-controlled, adaptive seamless Phase II/III design (ASD). We propose the administration of an investigational drug in patients with high predicted short-term mortality secondary to COVID-19 disease. 80 patients were randomly assigned in a 1:1:1 ratio to three study arms that will receive clazakizumab at a dose of 12.5 mg, 25 mg or placebo. Interim analyses have occurred every 7 days since the enrollment of the first 30 patients. Based on week 4 interim analysis the DSMB has recommendation discontinuing the low-dose 12.5 mg of clazakizumab arm. The DSMB has advised continuing enrollment in the placebo and high-dose 25mg of clazakizumab arms in a 1:1 randomization.,Treatment,Double (Participant, Investigator),This study is double-blind and therefore neither the Investigator, the subject, the Sponsor and its representatives, nor other designated study site personnel involved in running of the study will be aware of the identification of the investigational drug administered to each subject.","gender:All,Min Age:18 Years,Max Age:N/A",No,90
NCT04341441,Recruiting,"April 7, 2020","April 30, 2021","COVID-19,Coronavirus,Coronavirus Infections,SARS-CoV 2","Randomized,Parallel Assignment,This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW) and first responders (FR) in southeast (SE) Michigan, can prevent the acquisition, symptoms and clinical COVID-19 infection.
The study will randomize a total of 3,000 Healthcare Workers and First Responders, age ≥18 years or older, through the Henry Ford Health System, Detroit COVID Consortium. The participants who meeting study entry criteria and are not on HCQ prior to study enrollment will be randomized in a 1:1:1 blinded comparison of daily or weekly oral hydroxychloroquine versus oral placebo for 8 weeks.
A fourth non-randomized comparator group will be enrolled in the study comprising of HCW who are chronically on HCQ as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy.,Prevention,Triple (Participant, Care Provider, Investigator),Blinded randomization will be performed by the Henry Ford Hospital Public Health Sciences investigators once the participants are determined to be eligible for enrollment. Randomization will be stratified by study site and risk of exposure based on location of work and type of work.
Once enrolled, each Participant will be assigned a unique identifier (detailed in the full protocol). This number, along with the assigned site number, will constitute the Subject Identifier (Subject ID).","gender:All,Min Age:18 Years,Max Age:75 Years",No,3000
NCT04316728,Not yet recruiting,March 2020,November 2020,Coronavirus Infections,"N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04573361,Completed,"May 2, 2020","May 27, 2020","Musculoskeletal Pain,Disability Physical,Psychological Distress","Non-Randomized,Parallel Assignment,Three arms depending on the access to chiropractic care (no access, one visit or more than one) during the 14-days period of the trial. Measures were taken at the beginning and at the end of the 14-day period.,Treatment,None (Open Label),Care was provided by chiropractors,","gender:All,Min Age:14 Years,Max Age:N/A",No,723
NCT04422769,Recruiting,"May 22, 2020","December 31, 2020",Spinal Cord Injuries,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,250
NCT04445220,Not yet recruiting,September 2020,July 2021,"COVID-19,Acute Kidney Injury","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,22
NCT04318431,Completed,"April 14, 2020","June 1, 2020",Covid19,"N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:N/A,Max Age:15 Years",No,605
NCT04366063,Recruiting,"April 5, 2020","December 10, 2020",Covid-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,60
NCT04346277,Available,N/A,N/A,N/A,N/A,"gender:All,Min Age:18 Years,Max Age:70 Years",N/A,N/A
NCT04355611,Recruiting,"April 20, 2020","April 20, 2022","Multiple Sclerosis,NMO Spectrum Disorder,COVID-19","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,2000
NCT04333420,Recruiting,"March 31, 2020","August 31, 2021",Severe COVID-19 Pneumonia,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator),Phase II: Open label study (30 patients) Phase III: Double- blind; (360 patients)","gender:All,Min Age:18 Years,Max Age:N/A",No,390
NCT04331054,Recruiting,"April 13, 2020","January 13, 2022","Covid-19 Infection,Hospitalization in Respiratory Disease Department","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,436
NCT04386850,Recruiting,"April 14, 2020","March 15, 2021",COVID 19,"Randomized,Parallel Assignment,This is a multicenter randomized double-blinded placebo-controlled clinical trial with parallel groups and allocation 1:1.,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),All subjects in a stratified random sampling method based on age, sex, BMI and serum level of 25(OH)D (<10 ng/dL vs 10 to <20 ng/dL) with serum calcium <=10.6 mg/dL will be recruited in the 25(OH)D3 or placebo group. The clinical coordinator will determine this with a computer-generated randomization program. Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.","gender:All,Min Age:18 Years,Max Age:75 Years",No,1500
NCT04341103,Not yet recruiting,"April 1, 2020","March 1, 2021","Solid Organ Transplant Rejection,COVID-19","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,500
NCT04568876,Not yet recruiting,October 2020,November 2021,Covid19,"Randomized,Parallel Assignment,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04381936,Recruiting,"March 19, 2020",December 2031,Severe Acute Respiratory Syndrome,"Randomized,Factorial Assignment,Main randomisation (part A): Eligible patients will be randomly allocated between the available treatment arms.
Main randomisation (part B): Simultaneously, eligible patients will be randomly allocated between convalescent plasma, synthetic neutralizing antibodies or no additional treatment.
Subsequent randomisation: Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo an optional second randomisation.,Treatment,None (Open Label)","gender:All,Min Age:N/A,Max Age:N/A",No,15000
NCT04389385,"Active, not recruiting","May 1, 2020","May 31, 2021","Corona Virus Infection,Pneumonia","N/A,Single Group Assignment,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,60
NCT04448717,Recruiting,"June 16, 2020",March 2021,"SARS-CoV 2,COVID-19","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:5 Years,Max Age:N/A",No,8000
NCT04425382,Recruiting,"March 1, 2020",September 2020,"Coronavirus,COVID,Pneumonia","Other,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04443075,Recruiting,"June 24, 2020","August 30, 2020","Stress Disorders, Post-Traumatic","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:50 Years",No,180
NCT04341727,Suspended,"April 4, 2020","August 1, 2021",Coronavirus Infection,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04377750,Recruiting,"April 8, 2020","May 8, 2021",Covid19 Pneumonia,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04409275,Recruiting,"May 21, 2020","July 31, 2021",Pulmonary Fibrosis,"Case-Only,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:90 Years",No,500
NCT04403100,Recruiting,"June 3, 2020","November 28, 2020","COVID-19,Coronavirus Infection,Virus Disease,Acute Respiratory Infection,SARS-CoV Infection","Randomized,Factorial Assignment,Patients will be randomly allocated to one of four treatment arms in a 1:1:1:1 ratio:
Lopinavir / Ritonavir
Hydroxychloroquine
Lopinavir / Ritonavir + Hydroxychloroquine
Placebo.
We will use a centralized random allocation schedule, generated by computer and implemented using an online remote access system. Randomization will be stratified by participating basic health unit.,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),The investigational medical product will be packaged in similar bottles by a third party who will keep the allocation confidential until the end of the study. The bottles will be sealed and identified as ""Research Product A, B and C"" and with different colored labels. They will be randomly allocated among the participants. The research subjects, medical assistance, administrative and health staff will not have access to the contents of the bottles. The Arm Lopinavir/ ritonavir plus hydroxychloroquine will receive two of such bottles.
At the end of the study, after the statistical analysis and DMSB meeting, it will then be requested from third party documentation on content of each bottle and then have arms identified.","gender:All,Min Age:18 Years,Max Age:N/A",No,1968
NCT04340349,Enrolling by invitation,"May 11, 2020","August 20, 2020","Hydroxychloroquine,Antimalarials,Enzyme Inhibitors,Antirheumatic Agents","Randomized,Parallel Assignment,Parallel Assignment,Prevention,Triple (Participant, Care Provider, Investigator),DOUBLE BLINDED","gender:All,Min Age:18 Years,Max Age:N/A",No,140
NCT04560205,Recruiting,"May 1, 2020","October 30, 2020",SARS-CoV Infection,"N/A,Single Group Assignment,quasi-experimental,Treatment,None (Open Label)","gender:All,Min Age:15 Years,Max Age:80 Years",No,50
NCT04452422,Recruiting,"June 23, 2020","September 23, 2020",Deep Venous Thrombosis,"Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04350320,Recruiting,"April 30, 2020","November 20, 2020",COVID19,"Randomized,Parallel Assignment,Phase III, prospective, randomized, controlled, open-label and pragmatic trial, comparing the administration of colchicine plus standard treatment vs. standard therapy, in hospitalized patients with COVID-19, within the first 48 hours, and no severity criteria,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,102
NCT04345445,Not yet recruiting,"April 15, 2020","October 31, 2020",COVID-19,"Randomized,Crossover Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,310
NCT04367870,Recruiting,"May 23, 2020",May 2021,Oncology,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2500
NCT04416464,Not yet recruiting,"June 15, 2020","October 1, 2022","Quality of Life,Long-term Outcomes,Coronavirus Infection,Morality,Rehospitalization","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,230
NCT04493242,Not yet recruiting,"September 1, 2020","December 31, 2020","Covid19,ARDS,Pneumonia, Viral","Randomized,Parallel Assignment,Multi-center, placebo-controlled, randomized clinical trial.,Treatment,Single (Investigator)","gender:All,Min Age:18 Years,Max Age:85 Years",N/A,60
NCT04381338,Not yet recruiting,"May 10, 2020","September 30, 2020","Corona Virus Disease 19 (COVID-19),COVID,Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS),Critical Illness","Non-Randomized,Parallel Assignment,Clustered, due to catchment area of Hospital with no chance of contamination because of lock down in the area.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,92
NCT04273763,"Active, not recruiting","February 16, 2020","June 1, 2020","Novel Coronavirus Pneumonia,2019-nCoV","Randomized,Sequential Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,18
NCT04470609,Enrolling by invitation,"July 10, 2020",November 2021,COVID-19,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:60 Years,Max Age:N/A",No,471
NCT04563065,Recruiting,"August 1, 2020","December 31, 2023","Pregnancy Complications,Pregnancy, High Risk,Pregnancy Induced Hypertension,Newborn Morbidity,Fetal Growth Retardation,Fetus Disorder,Weight Gain, Maternal,Maternal-Fetal Relations","Randomized,Parallel Assignment,Prevention,Single (Outcomes Assessor)","gender:Female,Min Age:18 Years,Max Age:50 Years",No,280
NCT04449783,Recruiting,"June 25, 2020","September 25, 2020","Covid19,Cancer","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,150
NCT04369469,Recruiting,"May 11, 2020",February 2021,"COVID-19 Severe Pneumonia,Acute Lung Injury,Acute Respiratory Distress Syndrome,Pneumonia, Viral","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,270
NCT04550312,Recruiting,September 2020,October 2020,"Lifestyle Alteration,Non-COVID Deaths","Other,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,80000
NCT04408391,Withdrawn,"May 20, 2020","July 6, 2020","Covid-19,Anosmia","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT03808922,Recruiting,"May 23, 2019","December 28, 2021","Lower Respiratory Tract Infection,Parainfluenza,Immunocompromised,COVID-19","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:N/A,Max Age:N/A",No,250
NCT04407169,Not yet recruiting,"June 1, 2020","August 1, 2020",COVID,"Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04466657,Not yet recruiting,"November 1, 2020","April 30, 2021",Covid-19,"Randomized,Parallel Assignment,Supportive Care,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:75 Years",No,90
NCT04361942,Recruiting,April 2020,"December 31, 2020",COVID-19 Pneumonia,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Care Provider, Investigator),Both experimental and Placebo will receive a similar endovenous injection with either cells or placebo. Blind to participant, investigator ans care providers","gender:All,Min Age:18 Years,Max Age:N/A",No,24
NCT04421625,Recruiting,"June 15, 2020","June 15, 2022",COVID-19,"N/A,Single Group Assignment,Screening,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,12000
NCT04372056,Recruiting,"May 6, 2020","May 6, 2021","COVID-19,Critical Care,Intensive Care Units,Health Personnel","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:20 Years,Max Age:N/A",No,2200
NCT04361344,Recruiting,"May 19, 2020","January 19, 2021","COVID-19 Infection,Encephalitis","N/A,Single Group Assignment,Prospective, descriptive, monocentric, non-controlled study,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04507230,Recruiting,"August 7, 2020",October 2020,Coagulopathy,"Cohort,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04536935,Not yet recruiting,September 2020,December 2020,"Depression,Anxiety,Emotional Regulation","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:19 Years,Max Age:N/A",No,2000
NCT04438967,Recruiting,"June 16, 2020","December 31, 2020",Brain Health,"Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,10000
NCT04498546,Recruiting,"July 20, 2020","September 30, 2021",Exercise Test,"Other,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:65 Years",No,60
NCT04428801,Not yet recruiting,"August 1, 2020","October 30, 2021",COVID-19,"Randomized,Parallel Assignment,The Phase 2 study is a randomized, double-blind, placebo-control study conducted in multiple clinic facilities.,Treatment,Double (Participant, Outcomes Assessor),Patients and evaluators","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04445389,Recruiting,"June 17, 2020","June 17, 2022",SARS-CoV-2,"Randomized,Parallel Assignment,Prevention,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:50 Years",No,210
NCT04373213,Not yet recruiting,"May 5, 2020","June 15, 2020",Pleth Variability Index,"Case-Control,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04512300,Completed,"June 15, 2020","June 25, 2020",Dental Treatment During Covid -19,"Other,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,267
NCT04374058,"Active, not recruiting","March 20, 2020",March 2021,End Stage Renal Disease,"Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:85 Years",No,50
NCT04480957,Recruiting,"August 4, 2020",January 2021,SARS-CoV-2,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:21 Years,Max Age:80 Years",No,92
NCT04392414,Completed,"May 1, 2020","September 23, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,60
NCT04392245,Completed,"April 15, 2020","April 26, 2020",Proctologic Practice During COVID-19,"Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1050
NCT04477902,Recruiting,"July 1, 2020","July 1, 2022","Covid19,Corona Virus Infection,Quality of Life,Risk Reduction","Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,50000
NCT04325646,Recruiting,"March 13, 2020","February 28, 2023","SARS (Severe Acute Respiratory Syndrome),COVID-19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:5 Years,Max Age:N/A",No,2000
NCT04403828,Completed,"May 20, 2020","July 15, 2020",COVID 19,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:75 Years",No,323
NCT04336761,Recruiting,"April 15, 2020",January 2021,"Coronavirus,COVID,Infection Viral","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:18 Years",No,914
NCT04470427,Recruiting,"July 27, 2020","October 27, 2022",SARS-CoV-2,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,30000
NCT04346979,Not yet recruiting,"August 1, 2020","November 1, 2020",Telerehabilitation,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:Female,Min Age:45 Years,Max Age:65 Years",No,50
NCT04379375,Terminated,"July 27, 2020","September 30, 2020","Health Behavior,COVID-19","Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,45
NCT04531774,Recruiting,"August 28, 2020","June 1, 2021","Stress,Burnout,Anxiety,Depression,Covid19","Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,160
NCT04398264,Recruiting,"July 22, 2020","March 31, 2021","Corona Virus Infection,Pregnancy Related","Cohort,Other","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,100
NCT04426266,Completed,"May 1, 2020","September 28, 2020","Questionnaire Designs,COVID-19 Pandemic,Psychological Stress,Coping Skills,Two-Item Generalised Anxiety Disorder Scale,Patient Health Questionnaire Anxiety and Depression Scale,Health Status Index,Subjective Health Complaint,Mood","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,441
NCT04497987,Recruiting,"August 2, 2020","June 29, 2021","COVID-19,SARS-CoV2","Randomized,Parallel Assignment,Prevention,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,2400
NCT04367714,Recruiting,"March 15, 2020","December 1, 2021","COVID,Terminal Renal Insufficiency","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04517123,Recruiting,"September 1, 2020","December 31, 2021","Covid19,Pneumonia, Viral","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04339608,Recruiting,"April 2, 2020","June 30, 2020",COVID-19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,10000
NCT04530448,Not yet recruiting,"September 30, 2020",March 2021,"COVID,Coronavirus,Coronavirus Infection,AKI,Acute Kidney Injury","Randomized,Parallel Assignment,Group 1 (control) will receive standard of care treatment for coronavirus according to institutional protocols.
Group 2 (treatment) will receive sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04542200,Enrolling by invitation,"January 1, 2021","December 31, 2022",Covid19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,70812
NCT04534608,"Active, not recruiting","May 11, 2020","March 31, 2021","SARS-CoV-2,Covid19","Family-Based,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:18 Years",No,6000
NCT04402866,Recruiting,"June 24, 2020",October 2020,"Acute Lung Injury (ALI) Associated With COVID-19,Lung Inflammation Associated With COVID-19","Randomized,Parallel Assignment,Parallel group, randomized, double-blind, placebo-controlled,Treatment,Triple (Participant, Care Provider, Investigator),Pharmacist & Sponsor are not blinded for Part 1. Pharmacist & Sponsor are blinded for Part 2.","gender:All,Min Age:18 Years,Max Age:80 Years",No,159
NCT04383886,Recruiting,"April 18, 2020","August 18, 2020","Emergency Department Staff During the COVID-19 Pandemic,Emergency Department Staff's Level of Stress","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04497389,Not yet recruiting,"September 15, 2020","September 15, 2021",SARS CoV-2,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04536376,Not yet recruiting,"November 1, 2020","December 31, 2021","Resilience,Stress,Sleep","N/A,Single Group Assignment,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,10
NCT04426253,"Active, not recruiting","June 5, 2020","July 31, 2021","COVID-19,Sars-CoV2","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04445441,Recruiting,"April 24, 2020","December 31, 2020",Coronavirus Infection,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:99 Years",No,150
NCT04369365,Recruiting,"April 27, 2020","December 27, 2020",COVID,"Randomized,Parallel Assignment,Prevention,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04491071,Not yet recruiting,September 2020,December 2020,Stress Disorder,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,405
NCT04550325,Recruiting,"August 5, 2020",February 2021,"Covid19,Pneumonia, Viral","N/A,Single Group Assignment,A Phase 1/2 Open Label, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients with Pneumonia,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,12
NCT04568096,Not yet recruiting,September 2020,November 2020,the Lung Complication of COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,160
NCT04395807,Recruiting,"June 3, 2020",May 2021,"COVID,Acute Hypoxemic Respiratory Failure","Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04377737,Withdrawn,"May 15, 2020",September 2020,"Infection; Viral, Coronavirus","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:3 Years,Max Age:10 Years",No,0
NCT04435522,Recruiting,"September 21, 2020",January 2021,COVID,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:99 Years",No,16
NCT04441489,Completed,"March 27, 2020","May 27, 2020","COVID-19,FDG PET/CT,Inflammation","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:99 Years",No,13
NCT04362111,Recruiting,"July 29, 2020",March 2021,"Cytokine Storm,COVID-19","Randomized,Parallel Assignment,Two parallel treatment arms,Treatment,Triple (Participant, Care Provider, Investigator),Investigator, care provider, and participant blinded","gender:All,Min Age:18 Years,Max Age:80 Years",No,30
NCT04395716,Not yet recruiting,July 2020,November 2021,"COVID,Covid-19,Corona Virus Infection,Sars-CoV2,Coronavirus-19,SARS Pneumonia,SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere","N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,50
NCT04514900,Recruiting,"September 23, 2020","September 15, 2021",Obesity,"Randomized,Factorial Assignment,A 2x2 randomized controlled pilot study will be conducted which randomly allocates up to 120 individuals with overweight or obesity to an online weight control program and varies whether they receive asynchronous social support (discussion board) vs synchronous plus asynchronous social support (weekly video chat + discussion board) and varies whether the type of feedback which they receive on their self-monitoring (detailed vs basic) in a factorial study. All participants will receive the core 16-week online interactive behavioral weight loss program (iREACH) and will be followed for 4 months with monthly surveys and weight ascertainment.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04508439,Recruiting,"June 20, 2020","December 30, 2020","Covid19,Pneumonia,Coagulation Disorder,Pulmonary Embolism","Randomized,Crossover Assignment,Initially they will be randomized into two blocks, the first based on prophylactic Enoxaparin (Numbers 1 to 64) and the second (Numbers 65 to 128) will be assigned to the Enoxaparin therapeutic regimen arm at doses of 1mg / kg/dose twice up to date
During hospitalization, the clinical evolution will be evaluated according to the requirements of mechanical ventilation, the reduction in D-Dimer levels and the clinical outcome (discharge or death).
Those patients who are discharged will be Randomized in two following treatment arms
The allocation of patients in the outpatient stage will be carried out randomly 1: 1 to receive Rivaroxaban 10mg PO every 24hrs or only clinical follow-up.
Follow-up of adverse events will be carried out in the Hematology outpatient clinic with a first consultation 15 days after discharge and a second consultation 30 days after discharge. With dimer D, ferritin, protein C, blood count, ESR and on day 30 with CAT.,Treatment,Double (Participant, Care Provider)","gender:All,Min Age:18 Years,Max Age:90 Years",No,130
NCT04563702,Recruiting,September 2020,October 2021,Covid19,"Non-Randomized,Sequential Assignment,Open-label, repeat dose, dose ranging,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:54 Years",No,48
NCT04344106,Recruiting,"April 1, 2020","May 1, 2020","Coronavirus Infection,Oxygen Deficiency","N/A,Single Group Assignment,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,25
NCT04536350,Not yet recruiting,September 2020,March 2022,"Covid19,Corona Virus Infection,ARDS,Aviptadil","Randomized,Parallel Assignment,Patients will be randomly allocated to receive either Aviptadil together with standard care or the placebo (NaCl 0.9%) together with standard care,,Treatment,Double (Participant, Investigator),Patients and the investigator administering inhalation devices of drug or placebo are not aware of which group they have been randomized to (double-blinded). Someone not involved in the study (e.g. the hospital pharmacist or a nurse not involved in study) prepares the inhalation devices with either drug or placebo according to the randomization plan received by the CTU","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04406246,Recruiting,"May 21, 2020","December 31, 2020",Coronavirus Infection,"N/A,Single Group Assignment,In this cohort study, all health workers of the Maternal-Perinatal Hospital ""Mónica Pretelini Sáenz"", with symptoms of SARS-CoV-2 will be treated promptly with nitazoxanide.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,150
NCT04367337,"Active, not recruiting","March 25, 2020","March 24, 2021",Health Behavior,"Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,6079
NCT04492384,Recruiting,"June 11, 2020","January 15, 2022","Covid19,SARS-CoV-2 Infection,Pneumonia,Copd,CKD,Cardiac Event,Overweight and Obesity,Cardiovascular Diseases,Diabetes,Hypertension,Coronary Heart Disease","Cohort,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,3500
NCT04525404,Not yet recruiting,November 2020,"September 1, 2021","Covid19,Coronavirus Infection,SARS-CoV Infection","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,228
NCT04360278,Recruiting,"April 21, 2020","April 14, 2030",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1500
NCT04346615,Recruiting,"April 25, 2020",April 2021,COVID-19 Infection,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04377607,Recruiting,"November 1, 2020","December 30, 2020",Corona Virus Infection,"Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,200
NCT04393636,Recruiting,"June 5, 2020","December 31, 2022","Cardiovascular Diseases,Cardiovascular Risk Factor","Randomized,Parallel Assignment,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,394
NCT04473599,Recruiting,"April 17, 2020","April 1, 2021","Depressive Symptoms,Anxiety,COVID-19","Randomized,Parallel Assignment,Prevention,Single (Participant),Participants are randomized to receive messages according to a random schedule (within a mico-randomized trial) or delivered via a reinforcement learning policy","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04500067,Recruiting,"May 7, 2020","September 30, 2020","Covid19,Pneumonia","Randomized,Parallel Assignment,Open-label multicenter randomized controlled in parallel groups.
Patients undergoing screening are randomized into groups in equal proportions:
Study Group (receive IVIG Bioven with base therapy).
Control group (receive base therapy only)
At the stage of Data Analysis to ensure comparability of data and homogeneity of the sample, the possibility of additional comparison of groups based on the actually prescribed base therapy and other identified covariates is provided.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,76
NCT04578236,Not yet recruiting,November 2020,January 2021,Covid19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,360
NCT04573868,Recruiting,"March 1, 2020","September 30, 2020",Mortality,"Case-Only,Prospective","sampling_method:Probability Sample,gender:All,Min Age:14 Years,Max Age:N/A",No,1000
NCT04329611,Terminated,"April 13, 2020","July 20, 2020",COVID-19,"Randomized,Single Group Assignment,Randomization will be conducted using an online tool. The use of an online tool will allow for dynamic randomization which ensures concealment of allocation. We will use a minimal sufficient balance randomization tool to ensure balance on age, sex, risk status (binary variable based on immune competence and other identified risks), days from symptom onset to randomization and provincial health zone (5 categories). These variables will be identified at telephone screening by a study coordinator, clarified with a physician when necessary, and entered into the online randomization tool. It is predicted that many patients will want treatment. Further, immunosuppressed patients may be at the highest risk of fatal outcomes. Therefore, we will use 2:1 randomization (HCQ: placebo).,Treatment,Triple (Participant, Care Provider, Investigator),A randomized, double-blind, placebo-controlled trial - trial staff and patients will all be blinded to the treatment allocation.","gender:All,Min Age:18 Years,Max Age:N/A",No,148
NCT04424797,Recruiting,"July 13, 2020",December 2020,COVID-19,"Randomized,Parallel Assignment,Prone vs. Supine positioning,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04456933,Recruiting,"June 29, 2020","February 28, 2022",Colon Cancer,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,148
NCT04377685,Recruiting,"March 1, 2020","September 30, 2020",COVID 19,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,800
NCT04283461,"Active, not recruiting","March 16, 2020","November 22, 2021","COVID-19,COVID-19 Immunisation","Non-Randomized,Sequential Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:99 Years",No,120
NCT04498442,Recruiting,"May 22, 2020","December 31, 2020","Covid19,Stress,Anxiety Depression","Randomized,Parallel Assignment,In this prospective randomized control trial, the effects of yoga practices are being compared between seasoned yoga practitioners with two controls who are age and gender matched and living in the same neighborhood.
One control group acts as active control who receives active intervention in the form of yoga activities during the study duration. The study provides its active control group an opportunity to learn and practice Simha-Kriya which involves deep breathing exercises and meditation. In contrast, the other control group acts as a placebo control and performs either reading activities or remains idle for 15 minutes throughout the study period.
The participants will be requested to complete a set of surveys as a part of the research activity. These surveys include validated scales on stress, resilience and well-being; and objective questions on COVID-19 infection and medical history.,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,30000
NCT04359693,Completed,"April 22, 2020","July 1, 2020",SARS-CoV 2,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1576
NCT04465656,Recruiting,"July 7, 2020","April 30, 2021",Pulmonary Embolism,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,250
NCT04386694,Recruiting,"May 18, 2020",July 2020,"COVID-19,Respiratory Failure","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),A researcher will program the device (PMBT/sMF or placebo) and will be instructed not to inform the patients or other researchers as to the type of treatment (PMBT/sMF or placebo). Therefore, the therapist responsible for the treatment, the investigators and the outcome assessors will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (PBMT/sMF or placebo).","gender:All,Min Age:15 Years,Max Age:N/A",No,30
NCT04390269,Not yet recruiting,"September 10, 2020","May 9, 2022",Genetic Predisposition to Disease,"Case-Control,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04456101,Recruiting,"June 19, 2020","June 1, 2022",COVID-19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:80 Years",No,240
NCT04403932,Recruiting,"April 17, 2020","July 1, 2020",Coronavirus Disease 2019 (COVID-19),"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04384887,Completed,"April 25, 2020","August 26, 2020","COVID,Anxiety,Depression, Postpartum","Case-Control,Prospective","sampling_method:Probability Sample,gender:Female,Min Age:18 Years,Max Age:45 Years",No,100
NCT04353011,Completed,"April 20, 2020","April 27, 2020","Sars-CoV2,Chronic Pain","Family-Based,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,312
NCT04478071,Recruiting,"August 22, 2020","August 1, 2022","Acute Respiratory Distress Syndrome,Coronavirus Infection","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04561154,Recruiting,"June 11, 2020","June 11, 2022","SARS-COV2,COVID19","N/A,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,134
NCT04385797,"Active, not recruiting","May 4, 2020","August 31, 2020","Mild Cognitive Impairment,Dementia","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:55 Years,Max Age:N/A",No,152
NCT04401410,Not yet recruiting,"October 30, 2020","August 15, 2021","SARS-CoV 2,Viral Infection,COVID 19","Randomized,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,58
NCT04460469,Recruiting,"July 1, 2020",September 2020,"Anxiety,Covid19,Oral Hygiene","Other,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1500
NCT04405934,Not yet recruiting,July 2020,April 2021,"Covid-19,Nosocomial Infection,Coronavirus,Coronavirus Infection,SARS-CoV 2","Sequential Assignment,Superiority model:
Baseline/control phase 1 Sample collection and genomic sequencing from Covid-19 positive participants suspected of acquiring infection in hospital (suspected nosocomial Covid-19 infection where tested positive >48 hours after hospital admission) where sequencing reports not interpreted/actioned by Infection Prevention Control (IPC) site teams
Site intervention phase Sample collection and genomic sequencing from Covid-19 positive participants suspected of acquiring infection in hospital where sequencing reports generated both rapid or standard and received by site IPC teams for interpretation and action
Control phase 2 (prospective) Sample collection and genomic sequencing from Covid-19 positive participants suspected of acquiring infection in hospital where sequencing reports not interpreted/actioned by IPC site teams - where deemed ethical and approved by oversight committees i.e. DMEC.,Health Services Research,None (Open Label)","gender:All,Min Age:N/A,Max Age:N/A",No,2000
NCT04331171,Recruiting,"March 17, 2020","July 31, 2020",COVID-19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,3000000
NCT04388605,Recruiting,"April 21, 2020",September 2022,"Corona Virus Infection,COVID,Pregnancy Related,Early Pregnancy","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,11000
NCT04492358,Not yet recruiting,September 2020,October 2021,Covid19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:65 Years,Max Age:N/A",No,144
NCT04353518,Not yet recruiting,"April 30, 2020","May 30, 2021",COVID-19,"Randomized,Parallel Assignment,Randomized, double-blind, two arms, placebo controlled, clinical trial,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04484545,"Active, not recruiting","April 1, 2020","June 1, 2021",COVID-19,"Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,250
NCT04407533,Recruiting,"May 25, 2020","August 31, 2022",COVID-19,"Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1920
NCT04456413,Not yet recruiting,October 2020,July 2021,COVID-19,"Randomized,Crossover Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,306
NCT04495842,Not yet recruiting,"August 1, 2020","April 30, 2021","Stress,Covid19,Anxiety","Randomized,Parallel Assignment,Supportive Care,Single (Participant)","gender:All,Min Age:18 Years,Max Age:65 Years",No,65
NCT04370197,Recruiting,"March 3, 2020","April 30, 2020","Stroke, Acute","Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04279782,Recruiting,"January 20, 2020","February 28, 2021",Coronavirus,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04444661,"Active, not recruiting","June 10, 2020","December 31, 2020","Osteoporosis,Sarcopenia","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:Male,Min Age:74 Years,Max Age:95 Years",No,21
NCT04531735,"Active, not recruiting","March 1, 2020","August 31, 2020","RSV Infection,Covid19","Case-Control,Prospective","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:1 Month",No,28
NCT04341675,Recruiting,"April 24, 2020",September 2020,COVID-19,"Randomized,Parallel Assignment,Randmized, double blind, placebo controlled,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04542915,Not yet recruiting,September 2020,October 2021,"SARS-CoV Infection,Anxiety,Depression,Occupational Problems,Severe Acute Respiratory Syndrome,Coronavirus Infection","Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,5000
NCT04337190,Recruiting,"April 3, 2020","December 6, 2020","COVID,Acute Respiratory Distress Syndrome","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04535778,Not yet recruiting,"September 28, 2020","June 1, 2021",Treatment of Illness-related Distress in Physical LTCs,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04434157,Completed,"March 28, 2020","May 5, 2020",Covid-19,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,221
NCT04336254,Recruiting,"April 6, 2020","March 31, 2021",COVID-19,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:65 Years",No,20
NCT04347993,Recruiting,"March 27, 2020",April 2021,COVID-19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,5000
NCT04392973,Recruiting,"May 21, 2020",November 2021,COVID19,"Randomized,Parallel Assignment,Randomized, open-label, parallel groups were participants are assigned to either an intervention arm or standard of care.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,520
NCT04507893,Recruiting,"March 15, 2020","December 1, 2020","Covid19,Interstitial Pneumonia","Case-Only,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:95 Years",No,80
NCT04507256,Recruiting,"August 18, 2020","September 14, 2021",COVID-19,"Randomized,Sequential Assignment,Treatment,Double (Participant, Investigator),The study will be blinded for all placebo controlled dose groups, ie, the Principal Investigator (PI), all clinical staff involved in the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.","gender:All,Min Age:18 Years,Max Age:55 Years",No,48
NCT04344002,Recruiting,"April 21, 2020","December 15, 2020","Covid-19,Lung Cancer","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,200
NCT04505722,Recruiting,"September 7, 2020","March 10, 2023",Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,60000
NCT04368975,Recruiting,"March 12, 2020","December 31, 2020",Acute Respiratory Failure With Hypoxia,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04374071,Completed,"March 12, 2020","April 30, 2020","COVID,Pneumonia, Viral","Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,250
NCT04305574,Completed,"March 7, 2020","April 21, 2020","Coronavirus,Depression,Anxiety,Stress","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:21 Years,Max Age:N/A",No,1145
NCT04468035,Recruiting,"June 1, 2020","December 31, 2021",Covid19,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04366323,Recruiting,"April 27, 2020",October 2021,Sars-CoV2,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,26
NCT04354519,Recruiting,"March 14, 2020","July 14, 2022","Multiple Sclerosis,COVID-19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,3000
NCT04525417,Recruiting,"April 25, 2020","October 25, 2020",Covid-19 Immune Status of Healthcare Workers,"Non-Randomized,Parallel Assignment,Monocentric, open-label, prospective, non-randomized study,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04373811,Recruiting,"April 16, 2020","September 16, 2021","COVID-19,ICU Acquired Weakness,Weaning Failure","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,50
NCT04510623,Recruiting,"March 17, 2020","June 30, 2022","COVID-19,SARS-CoV2","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04542083,Not yet recruiting,"December 1, 2020","June 30, 2021","COVID-19,Acute Cardiovascular Condition,Acute Neurovascular Condition,Stroke,Acute Myocardial Infarction","Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04359537,Recruiting,"May 1, 2020","September 25, 2020",COVID 19,"Randomized,Parallel Assignment,Participants fulfilling the eligibility criteria will be randomized to 4 arms by using Random Allocation Software version-2
Arm Intervention /treatment Experimental group 1: Hydroxychloroquine 400 mg twice a day 1,followed by 400 mg weekly for a total of 12 weeks
Experimental group 2:Hydroxychloroquine 400 mg on day 1 followed by 400 mg once every 3 weeks for a total of 12 weeks
Experimental group 3:Hydroxychloroquine 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks
Control Group :Placebo 200mg will be given on day 1 followed by Placebo 200mg every three weeks for a total of 12 weeks..,Prevention,Single (Participant)","gender:All,Min Age:18 Years,Max Age:60 Years",No,200
NCT04449627,Not yet recruiting,"August 31, 2020","January 31, 2021","Anxiety Disorders,Post Traumatic Stress Disorder,Depressive Disorder,Covid19","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,125
NCT04377802,Not yet recruiting,"May 17, 2020","December 30, 2020",COVID 19,"N/A,Single Group Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,400
NCT04331834,Suspended,"April 3, 2020","October 30, 2020",COVID-19,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,440
NCT04442282,Not yet recruiting,"June 22, 2020","July 13, 2020","Anxiety,Depression,Interpersonal Problem,Emotion Regulation","Other,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,5041
NCT04378582,Completed,"May 7, 2020","August 5, 2020","SARS-CoV 2,Respiratory Distress Syndrome, Adult,Corona Virus Infection,Critical Illness","Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:14 Years,Max Age:100 Years",No,1589
NCT04346017,Recruiting,"March 20, 2020",December 2020,COVID-19,"Non-Randomized,Parallel Assignment,Basic Science,None (Open Label)","gender:All,Min Age:N/A,Max Age:N/A",No,200
NCT04305457,"Active, not recruiting","March 21, 2020","April 1, 2022","Coronavirus Infections,Pneumonia, Viral,Acute Respiratory Distress Syndrome","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,67
NCT04353037,Recruiting,"April 7, 2020","June 15, 2021","Coronavirus,Corona Virus Infection","Randomized,Parallel Assignment,Treatment and prevention study,Treatment,Double (Participant, Care Provider),For PATCH 2: participant and care provider are blinded. For PATCH 3: Health care worker is blinded.","gender:All,Min Age:50 Years,Max Age:75 Years",No,850
NCT04406688,Not yet recruiting,"May 25, 2020",March 2021,"Acute Kidney Injury,COVID-19,ARDS","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04385043,Recruiting,"May 1, 2020","May 15, 2021",COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,400
NCT04501822,Recruiting,"July 19, 2020","December 31, 2021","Covid19,Cardiac Complication","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,380
NCT04349163,Completed,"May 10, 2020","June 25, 2020",Psychological,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,280
NCT04498299,Recruiting,"September 1, 2020","November 30, 2020","Echocardiography, Stress,COVID-19,Hypertension, Pulmonary","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:45 Years",No,30
NCT04407273,"Active, not recruiting","May 14, 2020","December 30, 2020","COVID,Statin,Cardiovascular Diseases","Case-Only,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1200
NCT04422535,Recruiting,"May 29, 2020","December 1, 2020","Coronavirus Infection,Intensive Care Patients","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04315480,"Active, not recruiting","March 12, 2020",May 2020,SARS Pneumonia,"N/A,Single Group Assignment,Simon's Two-stages Optimal Design,Treatment,None (Open Label),Radiologist will be blinded for sequence","gender:All,Min Age:18 Years,Max Age:90 Years",No,38
NCT04368026,Recruiting,"March 30, 2020","December 1, 2020","Surgical Procedure, Unspecified","Other,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:25 Years,Max Age:N/A",No,350
NCT04490174,Recruiting,"August 26, 2020","June 1, 2022",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2500
NCT04568863,Recruiting,"June 20, 2020","November 30, 2020","COVID-19,SARS-CoV 2,Coronavirus Infection","Randomized,Parallel Assignment,phase II, single-center, double-blind, randomized placebo-controlled trial,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,18
NCT04328454,Recruiting,"January 30, 2020","April 15, 2020",Coronavirus,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04464395,Recruiting,"July 1, 2020","August 31, 2021",COVID-19,"Sequential Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04363047,Not yet recruiting,"May 1, 2020","May 1, 2021",SARS Virus,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,125
NCT04255940,Recruiting,"January 20, 2020","April 30, 2020",Cardiovascular Death; Major Adverse Cardiovascular Events,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,12000
NCT04374526,Recruiting,"May 27, 2020","June 30, 2021",Coronavirus Disease 2019 )COVID-19),"Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:65 Years,Max Age:N/A",No,182
NCT04416347,Recruiting,"June 15, 2020","April 30, 2022","COVID,SARS-CoV 2","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,800
NCT04516837,Recruiting,"August 31, 2020",August 2022,Immune Thrombocytopenia,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,120
NCT04536090,Not yet recruiting,November 2020,May 2021,COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,150
NCT04561089,Enrolling by invitation,"July 13, 2020","December 31, 2020",SARS-CoV-2,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2000
NCT04355026,Recruiting,"April 10, 2020","July 31, 2020",Covid-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:19 Years,Max Age:N/A",No,90
NCT04459403,Recruiting,"June 8, 2020","September 15, 2020",Corona Virus Infection,"Case-Only,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04304313,Recruiting,"February 9, 2020","November 9, 2020",COVID-19,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,10
NCT04399980,"Active, not recruiting","May 20, 2020","May 31, 2021","COVID 19,SARS-CoV 2,Pneumonia","Randomized,Factorial Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04473261,Recruiting,"July 14, 2020","September 30, 2020","Covid19,SARS-CoV-2,Corona Virus Infection","Randomized,Parallel Assignment,Randomized, controlled, multi-armed, close-label, interventional study designed,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),empty capsule will be given as a placebo","gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04463758,Recruiting,"May 11, 2020",October 2022,"covid19 Infection,Pregnancy Complications,Neonatal Complications","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:N/A,Max Age:N/A",No,3060
NCT04416373,Recruiting,"March 22, 2020",December 2023,"Coronavirus Infection,Pregnancy Complications,Vertical Transmission of Infectious Disease,Breastfeeding,Neonatal Infection","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:16 Years,Max Age:55 Years",No,300
NCT04556604,Completed,"April 10, 2020","August 14, 2020",Consent,"Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,45
NCT04463420,Recruiting,"August 15, 2020","December 15, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:75 Years",No,224
NCT04443140,Completed,"March 15, 2020","July 10, 2020","Covid-19,Preeclampsia,Pregnancy Related","Cohort,Prospective","sampling_method:Probability Sample,gender:Female,Min Age:18 Years,Max Age:40 Years",No,131
NCT04426201,Not yet recruiting,"June 22, 2020","December 31, 2020","COVID-19,Lymphocytopenia","Randomized,Parallel Assignment,randomized controlled of treatment vs placebo,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Unblinded Pharmacist will prepare blinded syringes of colorless drug or placebo","gender:All,Min Age:25 Years,Max Age:80 Years",No,48
NCT04480580,Completed,"March 30, 2020","June 30, 2020","Covid19,Surgery,SARS (Severe Acute Respiratory Syndrome)","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04382417,Recruiting,"March 26, 2020","May 31, 2021","Covid-19,Critical Illness","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04492449,Not yet recruiting,September 2020,December 2022,"Exposure During Pregnancy,Corona Virus Infection","Other,Other","sampling_method:Probability Sample,gender:Female,Min Age:16 Years,Max Age:40 Years",No,260
NCT04531319,Recruiting,"August 15, 2020","September 15, 2020",Covid19,"Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:80 Years",No,60
NCT04479644,Recruiting,"July 13, 2020",March 2021,COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:49 Years",No,12
NCT04409899,"Active, not recruiting","March 20, 2020","December 31, 2020","COVID-19,Urologic Diseases,Surgery--Complications,Epidemic Disease","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,300
NCT04419571,Completed,"March 23, 2020","June 16, 2020","COVID-19,Emergency General Surgery","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,94
NCT04563156,Enrolling by invitation,"June 23, 2020","December 31, 2021",Covid19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04397692,Recruiting,"June 13, 2020","September 30, 2020","Corona Virus Infection,COVID-19,SARS-CoV 2,Nitric Oxide,Respiratory Disease,Pneumonia, Viral,Inhaled Nitric Oxide","Randomized,Parallel Assignment,Device Feasibility,None (Open Label)","gender:All,Min Age:22 Years,Max Age:65 Years",N/A,20
NCT04435587,Not yet recruiting,July 2020,November 2021,"Asymptomatic Infections,SARS-CoV2 Infection","Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor),PCR for SAR-CoV2 detection will be performed by technician without knowledge of treatment arm","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04537975,Not yet recruiting,"September 15, 2020","January 15, 2021","Continuous Renal Replacement Therapy,Pulmonary Edema,COVID-19","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,30
NCT04433546,Recruiting,"July 15, 2020","December 18, 2020","Acute Respiratory Distress Syndrome,Coronavirus,Hypoxic Respiratory Failure,Hypoxemic Respiratory Failure,Respiratory Complication,Respiratory Insufficiency,Cardiac Dysfunction,Pneumonia,Pulmonary Edema,Pulmonary Inflammation,Respiratory Failure,Cytokine Storm,COVID 19,SARS-CoV-2,Cardiac Event,Cardiac Complication,Cardiac Failure,Cardiac Infarct","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:85 Years",No,210
NCT04461353,"Active, not recruiting","June 25, 2020","September 15, 2020",Severe Acute Respiratory Syndrome Coronavirus 2,"Randomized,Parallel Assignment,This is a randomized, double-blind placebo-controlled Phase 1 single-dose dose-escalation study to assess the safety, tolerability and PK of oral inhalation of AHCQ in healthy participants.
A sentinel dose strategy will be employed and the decision to escalate to the next dose level, or deescalate or stop the study, will be based on review and analysis of all available blinded safety and tolerability data by the Safety Review Committee (SRC), which will make a recommendation to the Sponsor and the Sponsor will inform the PI of the recommendation.,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,12
NCT04527432,Not yet recruiting,"November 1, 2020","December 31, 2020","Coronavirus Infection,Severe Acute Respiratory Syndrome","N/A,Single Group Assignment,Health Services Research,None (Open Label)","gender:All,Min Age:N/A,Max Age:N/A",No,3000
NCT04371328,"Active, not recruiting","March 13, 2020",March 2021,Emergencies,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:15 Years,Max Age:N/A",No,1860
NCT04307693,Terminated,"March 11, 2020","April 30, 2020",COVID-19,"Randomized,Parallel Assignment,Multicenter, open labelled, randomized clinical trial,Treatment,None (Open Label)","gender:All,Min Age:16 Years,Max Age:99 Years",No,65
NCT04328480,Recruiting,"April 17, 2020","August 30, 2020",COVID-19,"Randomized,Parallel Assignment,Simple pragmatic randomized open controlled trial,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,2500
NCT04343768,Completed,"April 9, 2020","April 27, 2020",COVID-19,"Randomized,Parallel Assignment,The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of the study.
Patients will be allocated to three therapeutic arms (Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a group and Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b group and the Base Therapeutic Regiment Group, i.e., Hydropinchloroquine + / Ritonavir. For this purpose, we will use the method of Balance Block Randomization for three groups.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04340219,Completed,"March 30, 2020","September 18, 2020",Cancer,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,394
NCT04454372,Not yet recruiting,"July 15, 2020","November 30, 2020",COVID-19,"Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:1 Year,Max Age:N/A",No,187
NCT04337489,Not yet recruiting,"July 28, 2020","April 1, 2021",Coronavirus,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:95 Years",No,200
NCT04548505,Not yet recruiting,September 2020,March 2023,SARS-CoV Infection,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04447534,Recruiting,"June 23, 2020","October 1, 2020",COVID,"Randomized,Parallel Assignment,Treatment,Double (Participant, Care Provider)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04397835,Recruiting,"April 17, 2020","April 20, 2021","COVID-19,Anxiety,Depression,Stress","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:50 Years,Max Age:89 Years",No,800
NCT04428073,Not yet recruiting,July 2020,December 2021,COVID,"Non-Randomized,Sequential Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,32
NCT04375098,Completed,"May 4, 2020","August 17, 2020",Severe Acute Respiratory Syndrome Coronavirus 2,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,58
NCT04358614,Completed,"March 16, 2020","April 7, 2020","COVID,Pneumonia","Non-Randomized,Crossover Assignment,Baricitinib treated patients compared with controls (previously COVID-19 receving standard therapy),Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:85 Years",No,12
NCT04569266,Recruiting,"August 7, 2020","May 7, 2022",Dyspnea,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04467918,Recruiting,"July 6, 2020","October 31, 2020",SARS-CoV2,"Randomized,Parallel Assignment,A total of 100 patients with SARS-CoV-2 infection will be included in the study (i.e., 50 cases in the CBD group plus pharmacological and clinical measures and 50 in the placebo group plus pharmacological and clinical measures). All patients will receive the clinical and pharmacological measures standardized by the Brazilian Ministry of Health's practical guidelines for diagnosis and treatment for mild and moderate cases for SARS-CoV-2,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04460599,Recruiting,"March 8, 2020","September 30, 2020",Encephalitis,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04487665,Not yet recruiting,"September 15, 2020","December 15, 2020",Covid19,"Ecologic or Community,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:40 Years",No,50
NCT04373486,Recruiting,"March 3, 2020","May 1, 2020",Covid-19 With Positive RT-PCR,"Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,160
NCT04263402,Recruiting,"February 1, 2020","July 1, 2020",2019-nCoV Severe Pneumonia,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04570202,Not yet recruiting,"October 15, 2020","July 15, 2022","Depression,Burnout, Professional,Post Traumatic Stress Disorder","Randomized,Parallel Assignment,Trials Within Cohort (TWIC) :
Participants are included within a cohort. They are screened using an online self-administered questionnaire for psychological distress (Post-Traumatic Stress Disorder, Burnout, Depression) every three months for one year.
People who are positive after screening (at M0 or M3 or M6) will be eligible for the trial and some of them will be randomly assigned to the treatment group. The rest of the cohort will be the second arm (control group).,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,900
NCT04412239,Recruiting,"April 20, 2020","September 20, 2020","TB - Tuberculosis,Patient Satisfaction","N/A,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04441996,Enrolling by invitation,"July 17, 2020",October 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04465474,Recruiting,"May 1, 2020","December 31, 2022",COVID-19,"Other,Other","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,3000
NCT04351919,Withdrawn,"May 5, 2020","July 15, 2020",Patients With COVID19,"N/A,Single Group Assignment,open, interventional, multicentric study,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,0
NCT04334512,Recruiting,"June 22, 2020",September 2021,"COVID-19,Corona Virus Infection,Coronavirus-19,Sars-CoV2","Randomized,Parallel Assignment,This is a Randomized, Double-Blind, Placebo-Controlled Phase II interventional Study,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,600
NCT04306705,Recruiting,"February 20, 2020","June 20, 2020","Covid-19,SARS,Cytokine Storm,Cytokine Release Syndrome,Tocilizumab","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:80 Years",No,120
NCT04452435,Recruiting,"July 21, 2020",September 2021,COVID-19,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:70 Years",No,100
NCT04374552,Not yet recruiting,"May 5, 2020",April 2021,SARS-CoV-2 Infection,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Study medication will be tablets containing either active drug or placebo","gender:All,Min Age:20 Years,Max Age:N/A",No,140
NCT04474288,Recruiting,"July 16, 2020",July 2021,Covid19 Immunology,"Case-Control,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04448704,Recruiting,"June 22, 2020","December 31, 2020",Mental Health Issue,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:21 Years,Max Age:N/A",No,1000
NCT04425889,Completed,"May 5, 2020","June 1, 2020","COVID-19,SARS-CoV 2","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:99 Years",No,156
NCT04434248,"Active, not recruiting","April 23, 2020",July 2020,COVID-19,"Randomized,Sequential Assignment,This is an adaptive, multicenter, open-label, randomized clinical study of Favipiravir versus standard of care (SOC) in hospitalized patients with moderate to severe COVID-19 pneumonia.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,330
NCT04493294,Not yet recruiting,November 2020,December 2021,COVID-19 Pneumonitis,"N/A,Single Group Assignment,Using low dose whole lung radiotherapy to older patients who develop COVID-19 pneumonitis to improve their survival compared to historical data,Treatment,None (Open Label)","gender:All,Min Age:65 Years,Max Age:N/A",No,500
NCT04346186,Enrolling by invitation,"April 15, 2020","August 1, 2021",COVID,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,30000
NCT04542122,Not yet recruiting,"September 3, 2020","August 2, 2021",Morals,"Randomized,Crossover Assignment,Other,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:99 Years",No,500
NCT04476914,Recruiting,"June 29, 2020","December 31, 2020","Respiratory Failure,SARS-CoV 2,Corona Virus Infection,Post Intensive Care Unit Syndrome,Family Members,Post Traumatic Stress Disorder,Anxiety,Depression","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,250
NCT04339660,Recruiting,"February 1, 2020","June 30, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Care Provider, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:75 Years",No,30
NCT04374084,Recruiting,"May 10, 2020",December 2021,"COVID-19,Convalescence","Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:70 Years",No,60
NCT04566770,Recruiting,"September 24, 2020","October 20, 2022",COVID-19,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:6 Years,Max Age:N/A",No,481
NCT04408209,Recruiting,"April 23, 2020","September 15, 2021",COVID-19 Infection,"N/A,Single Group Assignment,Single arm,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04420286,Recruiting,"May 6, 2020","June 5, 2020","Coronavirus Infections,COVID19 Outbreak in France","Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,9000
NCT04445870,Recruiting,"May 1, 2020",December 2020,Cancer,"Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04390516,Completed,"March 24, 2020","May 30, 2020","COVID-19,Coronavirus,Mortality,Mechanical Ventilation","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,197
NCT04453748,Enrolling by invitation,"June 8, 2020","November 30, 2021","COVID-19,Coronavirus Infection,Sars-CoV2,Complications","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:120 Years",No,200
NCT04513184,Recruiting,August 2020,"December 31, 2020",Covid19,"Randomized,Parallel Assignment,Multicenter, randomized, controlled trial adult patients with confirmed COVID-19 infection,Treatment,Double (Participant, Care Provider)","gender:All,Min Age:18 Years,Max Age:75 Years",No,60
NCT04530500,Enrolling by invitation,"August 13, 2020","August 31, 2021","Covid19,Androgen Receptor Gene Overexpression","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:Male,Min Age:18 Years,Max Age:90 Years",No,200
NCT04516512,Not yet recruiting,"September 1, 2020","January 1, 2021",COVID-19,"N/A,Single Group Assignment,Screening,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,2500
NCT04346043,Not yet recruiting,"April 20, 2020","December 1, 2020",Coronavirus Disease (COVID-19),"Case-Only,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:80 Years",No,100
NCT04367896,Completed,"March 24, 2020","April 17, 2020",COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION,"Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1819
NCT04346602,Recruiting,"February 1, 2020","December 1, 2020",COVID-2019,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:1 Year,Max Age:80 Years",No,132
NCT04406532,Not yet recruiting,"October 20, 2020","March 1, 2021",Covid-19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04393142,Recruiting,"May 5, 2020","June 15, 2020",Coronavirus Infection,"Other,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:1 Year,Max Age:N/A",No,92
NCT04363827,Recruiting,"May 14, 2020",March 2021,"COVID19,Hydroxychloroquine,Prophylaxis,Treatment,SARS-CoV-2","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,2300
NCT04328961,"Active, not recruiting","March 31, 2020","October 31, 2020","COVID-19,Corona Virus Infection,SARS (Severe Acute Respiratory Syndrome),SARS-CoV-2","Randomized,Parallel Assignment,Prevention,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:80 Years",No,829
NCT04348383,Recruiting,"April 8, 2020","January 15, 2021",COVID19,"Randomized,Parallel Assignment,Phase IIb prospective, multi-center, randomized, parallel, double blind, placebo controlled,Treatment,Double (Participant, Investigator),double blind","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04366986,Recruiting,"June 23, 2020","April 30, 2024",Covid-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,25000
NCT04465981,Recruiting,July 2020,June 2021,"COVID-19,Corona Virus Infection","Cohort,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04407286,Recruiting,"May 19, 2020","May 18, 2021","Covid 19,Vitamin D Deficiency","N/A,Single Group Assignment,This is an open label treatment study for people with COVID 19 and low levels of vitamin D,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04424849,Recruiting,"March 15, 2020","July 15, 2020",COVID-19,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04392323,Recruiting,"May 13, 2020","July 31, 2020",Sars-CoV2,"N/A,Single Group Assignment,Prospective Cohort,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04407299,Completed,"April 20, 2020","May 20, 2020",COVID,"Other,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:16 Years,Max Age:N/A",No,360
NCT04515225,Not yet recruiting,"September 15, 2020","September 15, 2020",HIV Infections,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04359849,Recruiting,May 2020,September 2022,Coronavirus Infection,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:7 Years,Max Age:N/A",No,500
NCT04427098,Recruiting,"May 22, 2020","October 30, 2020",COVID-19,"Non-Randomized,Parallel Assignment,The study consists of two parts:
a phase II single-arm interventional prospective study including all patients treated with the study drug;
an observational prospective cohort study including all patients screened for receiving the study drug but not included in the phase II study.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:90 Years",No,300
NCT04381923,Not yet recruiting,"August 15, 2020","May 15, 2021","Severe Acute Respiratory Syndrome Coronavirus 2,Hypoxemic Respiratory Failure,Pneumonia, Viral,COVID","Randomized,Crossover Assignment,This will be a randomized study with alternating treatment assignment in which all advanced respiratory units will be assigned to use one of two default interventions (helmet CPAP vs HFNO) as the first-line treatment for refractory hypoxemia (defined as an oxygen saturation (Sp02) of 92% or less on on ≥ 6 LPM (liters per minute) nasal cannula (NC) oxygen). The first-line treatment will be alternated in each unit at 14-day intervals. The initial assignment will be determined by a computer randomization scheme. Patients who are still on their assigned intervention during crossover will remain on that assigned intervention. A design with numerous short periods and frequent crossovers was selected to minimize the risk of changes over time in the patient population and usual care confounding trial results. A 14-day period is also felt to be the minimal time needed to ensure device availability and adherence.,Supportive Care,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04443803,Not yet recruiting,"July 1, 2020","August 31, 2020",COVID-19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:120 Years",No,9
NCT04356508,Not yet recruiting,"April 14, 2020","August 31, 2021","COVID-19,SARS-CoV-2,2019-nCoV,Pneumonia, Viral","Non-Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,15
NCT04468009,Recruiting,"June 25, 2020",June 2021,"SARS-Associated Coronavirus,Covid19,SARS-CoV Infection","Randomized,Sequential Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:100 Years",No,36
NCT04340050,"Active, not recruiting","April 10, 2020","December 31, 2021",Coronavirus,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,10
NCT04422340,Recruiting,"April 1, 2020","August 15, 2020","COVID-19 Disease, Severe Form","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:60 Years,Max Age:N/A",No,185
NCT04357041,"Active, not recruiting","April 17, 2020",April 2021,"ALL, Adult","Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04558320,Recruiting,"July 2, 2020","April 1, 2021",Coronavirus Infection,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04379271,Recruiting,"June 11, 2020",October 2020,COVID-19,"Randomized,Parallel Assignment,double-blind, placebo-controlled, randomized, parallel-group trial,Treatment,Double (Participant, Investigator),Trial participants, the investigator and all other personnel directly involved in the conduct of the trial will be blinded to treatment assignments.
To maintain the blind, IMU-838 and placebo tablets will have identical appearance, shape and color, and will have identical labeling and packaging. To minimize the potential for bias, treatment randomization information will be kept confidential by the responsible personnel and will not be released to investigators, other trial center personnel, or the Sponsor's designee(s).","gender:All,Min Age:18 Years,Max Age:N/A",No,230
NCT04352985,Available,N/A,N/A,N/A,N/A,"gender:All,Min Age:18 Years,Max Age:N/A",N/A,N/A
NCT04576728,Not yet recruiting,October 2020,March 2021,Covid19,"Randomized,Parallel Assignment,Subjects will be randomized on a 1:1 basis either to trimodulin or to placebo treatment stratified by center.,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),All bottles will be indistinguishable.","gender:All,Min Age:18 Years,Max Age:N/A",No,164
NCT04468087,Not yet recruiting,"October 7, 2020","December 31, 2021",COVID-19,"Randomized,Parallel Assignment,Randomized, double-blinded, multicenter, multi-arm, multi-stage, study. COVID-19 confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) hospitalized patients with ≤ 7 days duration of symptoms will be randomly assigned to receive antivirals with potential effectiveness for SARS-CoV-2.
The study is planned to be an adaptive phase II / III study. The phase II will be divided into 2 stages: first and second stages. First stage will allocate patients into a 5:5:5:5:5:1:1:1:1:1:1 allocation ratio (5 for each treatment group and 1 for placebo) and second stage will allocate into 2:2:1:1 (2 for each treatment group and 1 for placebo). The phase 3 study will then proceed in a 2:1 allocation (2 treatments for each placebo).,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),This is a double-blind study for participants of the same active drug and researchers. Both participant and investigator can know, after randomization, which medication they were allocated to. However, none will know whether the capsule to be administered is active or placebo, ensuring blinding within that specific group to which the participant was allocated.","gender:All,Min Age:18 Years,Max Age:90 Years",No,1134
NCT04501965,Enrolling by invitation,"June 1, 2020","September 30, 2020",Covid19,"Randomized,Parallel Assignment,Eligible consenting symptom-free patients with COVID-19 confirmed by a positive Polymerase Chain Reaction test were subjected to the 10 days of treatment allocated to each of the 3 arms of the trial. Virological clearance is assessed on days 3, 6 and 14. Side effects are noted throughout the trial period. Clinical, paraclinical and laboratory examinations are occasionally provided. Viral clearance, side effects, and the onset of COVID symptoms are evaluated and the data is statistically processed.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,231
NCT04497246,Recruiting,"May 29, 2020",December 2020,Covid19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,5000
NCT04371471,Completed,"March 1, 2020","April 30, 2020","Sars-CoV2,Covid19","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04437693,Not yet recruiting,"August 31, 2020","December 31, 2021",COVID 19,"Randomized,Parallel Assignment,An interventional, double-blind, placebo-controlled randomized trial,Prevention,Single (Participant),The process of keeping the study group assignment hidden after allocation will be used where the investigator and participants will be unaware of the drug.A double blind randomized clinical trial has been proposed having 250 subjects in each arm. 500 subjects will be selected using randomly permuted blocks of 2,4, and 8 for the random process to allocate subjects into the two groups equally by using computer software.","gender:All,Min Age:18 Years,Max Age:60 Years",No,500
NCT04548557,Not yet recruiting,"September 15, 2020","November 15, 2020",Covid19,"Randomized,Parallel Assignment,one group in conventional with routine therapy and interventional group will receive intravenous immunoglobulin therapy,Treatment,Double (Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:90 Years",No,60
NCT04339426,Recruiting,"April 20, 2020",April 2021,Covid19,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:95 Years",No,25
NCT04407546,Recruiting,"May 27, 2020","May 28, 2023",Immunosuppression,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,300
NCT04338906,Not yet recruiting,"June 1, 2020","December 31, 2021",COVID,"Randomized,Parallel Assignment,Evaluation of the efficacy and safety of hydroxychloroquine + camostat combination therapy in comparison to hydroxychloroquine + placebo in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,334
NCT04322773,Recruiting,"April 5, 2020","June 1, 2021",Corona Virus Disease,"Randomized,Sequential Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04513561,Not yet recruiting,December 2020,March 2021,"Inflammatory Disease,Covid19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,4500
NCT04392128,Withdrawn,"September 2, 2020","September 2, 2020","COVID19,Hematologic Malignancy","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04399967,Recruiting,"June 13, 2020","June 30, 2022",Smoking Cessation,"Randomized,Parallel Assignment,Health Services Research,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,842
NCT04233268,Recruiting,"April 6, 2020","February 28, 2025","Lower Respiratory Tract Infection,Ventilator Associated Pneumonia,COVID19","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:16 Years",No,250
NCT04546581,Not yet recruiting,September 2020,July 2021,"COVID,COVID-19,SARS-CoV-2,SARS (Severe Acute Respiratory Syndrome)","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04490473,Recruiting,"July 24, 2020","December 24, 2020","Anxiety,SARS-CoV Infection","N/A,Single Group Assignment,This research will be conducted in a methodological manner in order to conduct the validity and reliability studies of the Coronary Virus Anxiety Scale in Turkish.,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,300
NCT04371952,Not yet recruiting,"June 1, 2020","December 1, 2020",COVID19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator),Double blind","gender:All,Min Age:46 Years,Max Age:N/A",No,330
NCT04528329,Recruiting,"August 30, 2020","December 15, 2020","Covid19,Anosmia","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04259892,Recruiting,"February 4, 2020","February 4, 2021",Coronavirus,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,345
NCT04371744,Completed,"April 17, 2020","June 5, 2020",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04352751,Recruiting,"May 1, 2020",April 2021,Covid-19,"N/A,Single Group Assignment,Single arm, open label, clinical trial employing WHO recognized monitored emergency use of unregistered and experimental interventions (MEURI) study.,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:55 Years",No,2000
NCT04374474,Withdrawn,"January 10, 2021","March 10, 2022",Olfactory Disorder,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04390165,Not yet recruiting,May 2020,August 2020,"SARS-CoV Infection,COVID-19,Anosmia,Dysgeusia","Case-Only,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,760
NCT04378829,Recruiting,"September 12, 2020","October 21, 2020","Covid-19,Mean Platelet Volume,Platelet Destruction","Case-Only,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,40
NCT04341415,Recruiting,"April 9, 2020",March 2021,"Covid19,SARS-CoV Infection","Randomized,Parallel Assignment,Treatment,Double (Participant, Care Provider),The participants and the care providers will not know the arm of randomization. Only the principal investigator who will perform the intervention will know the type of intervention.","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04441684,Recruiting,"April 17, 2020",August 2021,"SARS-CoV-2 Serological Status,SARS-CoV-2 Seroprevalence","Non-Randomized,Parallel Assignment,Screening,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,1800
NCT04559009,Not yet recruiting,"October 15, 2020","April 30, 2024","Covid19,Amyotrophic Lateral Sclerosis","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04470648,Not yet recruiting,July 2020,November 2020,SARS-COV2 Infection,"Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,220
NCT04264533,Recruiting,"February 14, 2020","September 30, 2020","Vitamin C,Pneumonia, Viral,Pneumonia, Ventilator-Associated","Randomized,Parallel Assignment,Treatment,Triple (Participant, Care Provider, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,140
NCT04380727,Completed,"March 20, 2020","April 25, 2020","COVID-19,Hypoxic Respiratory Failure","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,17
NCT04524052,Not yet recruiting,August 2020,December 2020,Healthy,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:45 Years",No,32
NCT04576312,Recruiting,"June 29, 2020","December 31, 2020",COVID-19,"Randomized,Sequential Assignment,Other,Single (Investigator)","gender:All,Min Age:18 Years,Max Age:65 Years",No,44
NCT04382066,Recruiting,"May 12, 2020",November 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,27
NCT04405570,Recruiting,"June 16, 2020","November 15, 2020",SARS-CoV 2,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,108
NCT04389801,Not yet recruiting,"June 1, 2020","December 31, 2020",Covid 19,"Randomized,Parallel Assignment,Desferal group An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours.,Treatment,Single (Participant),Placebo group Will receive glucose 5% over 4 hrs infusion","gender:All,Min Age:N/A,Max Age:N/A",No,200
NCT04351529,Recruiting,"April 1, 2020",December 2021,"Infectious Disease,COVID-19","Other,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04334967,Suspended,"March 30, 2020","May 27, 2022","COVID-19,Corona Virus Infection,SARS-CoV-2,2019-nCoV,2019 Novel Coronavirus","Randomized,Parallel Assignment,Upon confirmation of positive nasopharyngeal test for SARS-CoV-2, eligible patients will be randomized 1:1 to either a treatment group or control group.,Treatment,Single (Outcomes Assessor),Analysts will be blinded to patient randomization; outcome data analyses will be conducted with patient identifiers removed.","gender:All,Min Age:45 Years,Max Age:N/A",No,13
NCT04389372,Recruiting,"March 15, 2020",December 2021,Migraine Headache,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,50
NCT04456452,"Active, not recruiting","July 27, 2020","November 13, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:89 Years",No,10
NCT04363853,Recruiting,"June 1, 2020","August 1, 2021",Sars-CoV2,"N/A,Single Group Assignment,Phase II, single-arm, open-label, prospective, blinded, clinical trial with Tocilizumab as the sole agent.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:90 Years",No,200
NCT04408170,Recruiting,"June 19, 2020","May 31, 2021","Coronavirus Infection,COVID-19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,1000
NCT04486313,Recruiting,"August 13, 2020","December 30, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:12 Years,Max Age:120 Years",No,800
NCT04358081,Completed,"May 1, 2020","July 27, 2020",Covid-19,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,20
NCT04351724,Recruiting,"April 16, 2020","December 31, 2020",COVID-19,"Randomized,Parallel Assignment,Three main study arms (antiviral treatments) and three substudies (A, B, C) are planned. The main study arms are exclusive, while patients from the main study arms may participate in one or more substudies.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:99 Years",No,500
NCT04342728,Enrolling by invitation,"April 8, 2020","April 30, 2021","COVID,Corona Virus Infection","Randomized,Single Group Assignment,A single-center, prospective, open label four arm study (1. Zinc only 2. Zinc and ascorbic acid 3. Ascorbic acid only 4. Standard of care.,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,520
NCT04371679,Recruiting,"April 1, 2020","December 1, 2020",Covid-19,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,40
NCT04459962,Recruiting,"June 29, 2020","June 14, 2021",Covid-19 Infection,"N/A,Single Group Assignment,Participants who are Covid-19 negative, Covid-19 positive or suspected with Covid-19 infection will be recruited,Diagnostic,None (Open Label)","gender:All,Min Age:16 Years,Max Age:N/A",No,250
NCT04346693,"Active, not recruiting","April 8, 2020",December 2020,"Acute Respiratory Tract Infection,Acute Respiratory Insufficiency,Pneumonia,Septic Shock,Hypoxemia","Randomized,Factorial Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,320
NCT04395391,Completed,"May 18, 2020","June 16, 2020",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04447833,Recruiting,"June 17, 2020","June 30, 2025","ARDS, Human,COVID","N/A,Single Group Assignment,This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS).,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,9
NCT04323345,Recruiting,"April 15, 2020","January 15, 2021",COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Investigator)","gender:All,Min Age:5 Years,Max Age:75 Years",No,1000
NCT04355494,Available,N/A,N/A,N/A,N/A,"gender:All,Min Age:18 Years,Max Age:N/A",N/A,N/A
NCT04365335,Completed,"April 25, 2020","June 12, 2020",Occupational Stress,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:60 Years",No,50
NCT04443725,Not yet recruiting,July 2020,December 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,100
NCT04343781,Completed,"March 22, 2020","April 5, 2020","SARS-CoV-2,COVID-19","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:70 Years,Max Age:N/A",No,353
NCT04378842,Recruiting,"May 18, 2020",May 2021,"Sars-CoV2,Critical Illness","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,690
NCT04275947,Recruiting,"February 14, 2020","May 31, 2020",COVID-19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:90 Years",No,450
NCT04470557,Not yet recruiting,"July 15, 2020","December 1, 2020",COVID-19,"Other,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04510038,Not yet recruiting,"September 1, 2020","January 1, 2022","Covid19,Myocardial Injury","Randomized,Parallel Assignment,Active group (Colchicine plus standard of care) vs Control group (standard of care alone),Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:100 Years",No,75
NCT04393415,Recruiting,"May 25, 2020","September 1, 2020",Virus,"Randomized,Parallel Assignment,Supportive Care,Double (Participant, Outcomes Assessor)","gender:All,Min Age:20 Years,Max Age:70 Years",No,100
NCT04374123,Completed,"April 20, 2020","June 15, 2020",COVID,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:80 Years",No,111
NCT04380779,Recruiting,"April 13, 2020","June 13, 2025",COVID-19,"Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,5000
NCT04433364,Recruiting,"June 2, 2020","June 2, 2041","Sars-CoV2,Covid-19,Pregnancy Complications,Pregnancy Preterm,Pregnancy in Diabetic,Neonatal Infection","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,1200
NCT04401254,Not yet recruiting,July 2020,April 2022,"COVID-19,Critical Illness","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04330521,Recruiting,"April 8, 2020",May 2022,"Cancer,COVID-19","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:99 Years",No,50
NCT04552951,Recruiting,"April 4, 2020","December 30, 2020",COVID-19,"Randomized,Parallel Assignment,Patients receiving any form. of vitamin D excluded from the study. Randomized study (Initial serum calcidiol levels blinded ),Treatment,Double (Participant, Outcomes Assessor)","gender:All,Min Age:N/A,Max Age:N/A",No,80
NCT04440098,Completed,"April 22, 2020","May 11, 2020","Loneliness,Depression,Anxiety,Alcohol Abuse,Drug Abuse","Case-Only,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:35 Years",No,1008
NCT04338009,Enrolling by invitation,"March 31, 2020","December 31, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,152
NCT04532372,Not yet recruiting,"September 18, 2020","September 18, 2022","Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm,Symptomatic COVID-19 Infection Laboratory-Confirmed","Randomized,Sequential Assignment,Phase I single-arm dose-escalation design followed by a phase II randomized two-arm design,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,30
NCT04365439,Not yet recruiting,"April 27, 2020","June 30, 2020","Blood Plasma Therapy,COVID","N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,10
NCT04488081,Recruiting,"July 31, 2020","November 1, 2022",COVID-19,"Randomized,Parallel Assignment,Platform Trial, Bayesian Design,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,1500
NCT04306055,Completed,"March 13, 2020","April 3, 2020",Blood Donation,"Randomized,Parallel Assignment,Health Services Research,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,19491
NCT04381884,Completed,"May 18, 2020","September 29, 2020",COVID-19 Drug Treatment,"Randomized,Parallel Assignment,Patients will be randomized to receive Ivermectin 600 µg / kg / once daily plus standard care or standard care upon diagnosis of COVID-19.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:69 Years",No,45
NCT04393402,Recruiting,"March 20, 2020","December 31, 2020",COVID,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:95 Years",No,14
NCT04558125,"Active, not recruiting","September 8, 2020","June 30, 2022","Pulmonary Embolism,COVID","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:75 Years",No,45
NCT04497454,Recruiting,"May 8, 2020","December 1, 2021","Respiratory Distress Syndrome,Severe Acute Respiratory Syndrome Due to Coronavirus (SARS-CoV2),Mechanical Ventilation","Randomized,Parallel Assignment,Prospective, randomized, single-center, open-label, superiority, controlled trial,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,128
NCT04385095,Recruiting,"March 16, 2020","May 31, 2021",SARS-CoV-2,"Randomized,Parallel Assignment,Randomised double-blind placebo-controlled
Pilot phase - 100 patients randomised in the hospital setting, 120 patients randomised in the home setting.
Pivotal phase - estimated at an additional 100 to 300 patients per arm, but the actual number will be determined after the data review at the end of the Pilot phase,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Double-blind","gender:All,Min Age:18 Years,Max Age:N/A",No,820
NCT04376658,Not yet recruiting,"June 15, 2020","September 15, 2021","Quality of Life,Long-term Outcomes,Coronavirus Infection","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04469114,Recruiting,"September 16, 2020","January 31, 2021",Covid19,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,260
NCT04416113,Not yet recruiting,August 2020,February 2021,Photodynamic Therapy& Low Level Laser in Management of COVID 19,"Randomized,Parallel Assignment,A randomized controlled study will be conducted on 60 patients of positive COVID 19. The patients will be divided into 3 equal groups. Group I will receive low level laser (diode laser 980nm) from laser watch for 30 minutes, 20 J for 3 to 5 days and laser acupuncture. Group 2 will be treated with photodynamic therapy by injecting the methylene blue as a photosensitizer and irradiated with laser watch (diode laser 670 nm). Group 3 will serve as a control. Evaluation methods will include laboratory investigations and CT chest.,Treatment,Single (Participant)","gender:All,Min Age:N/A,Max Age:N/A",No,60
NCT04382547,Enrolling by invitation,"May 11, 2020","June 30, 2021","COVID,Covid-19,Coronavirus,Pneumonia,Pneumonia, Viral,Pneumonia, Interstitial,Sars-CoV2","Non-Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:70 Years",No,40
NCT04472585,Recruiting,"July 14, 2020","September 30, 2020","Coronavirus Infection,COVID,Sars-CoV2","Randomized,Parallel Assignment,randomized, controlled, multi-armed, open-label, interventional study,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Empty capsule will sub-cutaneous injection of ivermectin will be used","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04391946,Recruiting,"March 14, 2020","December 31, 2022","Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04531501,Recruiting,"June 29, 2020","September 29, 2020",Covid19,"Cohort,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:117 Years",No,400
NCT04463823,Not yet recruiting,"July 6, 2020","May 31, 2025",COVID,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04338841,Completed,"April 9, 2020","June 17, 2020",Coronavirus Infection,"Non-Randomized,Sequential Assignment,Quasi-experimental before and after multicentre prospective study,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,3133
NCT04380987,Recruiting,"May 4, 2020","December 31, 2021",Covid19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04428008,Not yet recruiting,September 2020,August 2021,COVID-19,"Randomized,Parallel Assignment,Subjects will be centrally randomized to receive either study treatment drug (Ta1) or no Ta1. Randomization will be stratified by site.,Prevention,None (Open Label)","gender:All,Min Age:60 Years,Max Age:N/A",N/A,240
NCT04359511,Not yet recruiting,June 2020,December 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,210
NCT04557241,Not yet recruiting,October 2020,February 2021,COVID19 Behavioral Prophylaxis,"Randomized,Parallel Assignment,Prevention,Double (Participant, Outcomes Assessor),Although this is, in practice, a double-blind study since participants will be unaware that they are randomized and all study mechanics will be processed by computer, analysts will not be blinded to the meaning of the assignment variable. However, two independent consultant analysts have been retained to verify all results and subsequent interpretation.","gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04460690,Enrolling by invitation,"July 13, 2020",July 2021,"COVID-19,Sars-CoV2","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:5 Years,Max Age:N/A",No,10000
NCT04573348,Not yet recruiting,"October 10, 2020","October 10, 2021","Covid19,Corona Virus Infection","Other,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04429711,Recruiting,"May 12, 2020","October 31, 2020",COVID-19,"Randomized,Parallel Assignment,Double blind randomized,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:80 Years",No,100
NCT04410562,Recruiting,"May 13, 2020","August 1, 2021","Pregnancy Related,COVID,Covid-19","Randomized,Parallel Assignment,Randomized, double-blinded, placebo-controlled multicentre clinical trial.,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:Female,Min Age:N/A,Max Age:N/A",No,714
NCT04355429,Not yet recruiting,"May 5, 2020",August 2020,"Pneumonia,Coronavirus Infection,COVID-19","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,230
NCT04361474,Recruiting,"May 18, 2020","May 25, 2021","Budesonide,Olfaction Disorders,SARS-CoV-2,Anosmia","Randomized,Parallel Assignment,Patients with persistent hyposmia related to a SARS-CoV-2 infection,Treatment,Single (Participant),Patients with persistent hyposmia related to a SARS-CoV-2 infection","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04425850,"Active, not recruiting","June 1, 2020","August 10, 2020",Contagious Pleuropneumonia,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:5 Years,Max Age:N/A",No,70
NCT04395508,Available,N/A,N/A,N/A,N/A,"gender:All,Min Age:18 Years,Max Age:N/A",N/A,N/A
NCT04459676,Recruiting,"July 31, 2020",October 2020,"COVID-19,Pneumonia","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04412382,Recruiting,"June 1, 2020","December 31, 2021",Covid-19,"Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04393038,Recruiting,"May 1, 2020","April 30, 2021",COVID-19,"Randomized,Parallel Assignment,Phase 2/3, randomized, double blind, placebo-controlled study,Treatment,Triple (Participant, Care Provider, Investigator),Blinded treatment bottles","gender:All,Min Age:18 Years,Max Age:N/A",No,1034
NCT04556149,Recruiting,"October 1, 2020","December 31, 2020","Corona Virus Infection,Coronavirus","Case-Control,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:90 Years",No,30
NCT04444297,Not yet recruiting,"July 31, 2020","January 31, 2021","Telemedicine,Surgery, Plastic","Randomized,Crossover Assignment,Randomised to 2D then 3D, or 3D then 3D telemedicine consultations,Other,Double (Investigator, Outcomes Assessor),Investigator and outcomes assessor will be blinded to method of telemedicine. It is not possible to blind participants.","gender:All,Min Age:16 Years,Max Age:75 Years",No,40
NCT04348409,Recruiting,"May 25, 2020","July 31, 2020",COVID-19,"Randomized,Parallel Assignment,Patients will be randomized to receive either nitazoxanide or placebo (1:1).,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04433312,Not yet recruiting,"July 1, 2020","December 1, 2020","Satisfaction, Patient,Quality of Life","Other,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,10000
NCT04348929,Recruiting,"April 16, 2020","October 1, 2021",Postpartum Depression,"Non-Randomized,Parallel Assignment,Screening,None (Open Label)","gender:Female,Min Age:18 Years,Max Age:N/A",No,927
NCT04496128,Enrolling by invitation,"April 13, 2020","March 31, 2021","SARS-CoV 2,Neurologic Manifestations","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04392089,Recruiting,"May 1, 2020","May 1, 2021","COVID-19,Respiratory Failure","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04575571,Recruiting,"April 29, 2020","April 29, 2025",Psychosocial Impacts of the COVID-19 Pandemic,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:14 Years,Max Age:N/A",No,5000
NCT04418375,Not yet recruiting,June 2020,March 2022,COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04334876,Not yet recruiting,"April 1, 2020","January 1, 2021",SARS-CoV-2,"Ecologic or Community,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,340
NCT04364711,Not yet recruiting,"May 1, 2020","April 30, 2022","COVID-19,SARS-CoV 2","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,2000
NCT04326920,Recruiting,"March 24, 2020","December 31, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,80
NCT04456439,Available,N/A,N/A,N/A,N/A,"gender:All,Min Age:2 Months,Max Age:17 Years",N/A,N/A
NCT04540939,Not yet recruiting,October 2020,December 2021,Trauma,"Randomized,Parallel Assignment,Treatment,Double (Investigator, Outcomes Assessor),Statistician will not know the group assignment until blind is broken. Statistician randomizes the groups. Principal investigator will not know group assignment until blind is broken.","gender:All,Min Age:18 Years,Max Age:72 Years",No,60
NCT04335162,Recruiting,"February 28, 2020","August 28, 2020","COVID,Acute Coronary Syndrome,Myocardial Infarction,Myocarditis,Venous Thromboembolism,Deep Vein Thrombosis,Pulmonary Embolism","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04504032,Recruiting,"September 2, 2020",December 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,600
NCT04530396,Recruiting,"September 7, 2020","May 1, 2021",Covid19 Prevention,"Randomized,Parallel Assignment,Randomized double-blind placebo-controlled,Prevention,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:111 Years",No,40000
NCT04357860,Not yet recruiting,"April 27, 2020","July 27, 2020","SARS-CoV 2,SARS","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,120
NCT04414098,Not yet recruiting,"June 1, 2020","September 15, 2020",COVID-19,"N/A,Single Group Assignment,Experimental, open-label, prospective, single center, add-on (added to the standard treatment) study, compared with an historical control arm.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04385147,Completed,"May 18, 2020","July 5, 2020","Cholangitis, Secondary Biliary,Cholangiocarcinoma,Obstructive Jaundice,Pancreas Cancer,COVID-19,SARS-CoV-2","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,670
NCT04534569,"Active, not recruiting","September 4, 2020","October 5, 2020","Covid19,Acute Respiratory Failure,Acute Respiratory Distress Syndrome","Other,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:70 Years",No,40
NCT04541472,Recruiting,"May 1, 2020","December 1, 2020",Dental Surgeon,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:16 Years,Max Age:N/A",No,1000
NCT04563442,Not yet recruiting,"October 15, 2020","February 25, 2023",Covid19,"Case-Crossover,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,200
NCT04414904,Not yet recruiting,"June 10, 2020","May 14, 2021","Infertility, Male,Testosterone Deficiency","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:Male,Min Age:18 Years,Max Age:50 Years",No,100
NCT04377334,Not yet recruiting,October 2020,July 2021,"ARDS,COVID-19","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04422574,Completed,"May 1, 2020","May 30, 2020",Covid 19,"Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,97
NCT04407689,Recruiting,"June 8, 2020","December 30, 2020","COVID-19,Lymphocytopenia","Randomized,Parallel Assignment,randomized controlled of treatment vs placebo,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Double blind","gender:All,Min Age:25 Years,Max Age:80 Years",No,48
NCT04393948,Recruiting,June 2020,November 2020,SARS-CoV 2,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:40 Years,Max Age:N/A",No,48
NCT04337762,Recruiting,"April 6, 2020",July 2021,COVID-19,"Case-Control,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:110 Years",No,100000
NCT04342702,"Active, not recruiting","March 16, 2020",March 2021,"Follow-up,COVID-19,Infectious Diseases,Respiratory","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,504
NCT04534478,Not yet recruiting,"September 7, 2020","December 15, 2021",COVID-19 Pneumonia,"Randomized,Parallel Assignment,Parallel clinical trial with therapeutic intervention, randomized, open and controlled, of non-inferiority,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04437719,Recruiting,"June 29, 2020","December 31, 2021","Oncology,COVID-19","N/A,Single Group Assignment,As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04458519,Recruiting,"July 16, 2020","December 31, 2020",COVID-19 Infection,"Randomized,Parallel Assignment,Single-blinded, randomized, prospective trial,Treatment,Double (Care Provider, Outcomes Assessor),Investigator responsible for product allocation and blinding is not in contact with study participant and will only be made aware of the process of their evolution in case of emergency.
Study personel in daily contact with the patient are unaware of the patient treatment assignement and are thus blinded.","gender:All,Min Age:18 Years,Max Age:59 Years",No,40
NCT04347889,Not yet recruiting,"April 20, 2020","December 30, 2020",Covid-19,"Randomized,Parallel Assignment,Open label, controlled, RCT,Prevention,Single (Outcomes Assessor),Outcomes assessors will be masked to study assignment","gender:All,Min Age:18 Years,Max Age:N/A",No,1212
NCT04343053,"Active, not recruiting","April 8, 2020","June 9, 2021",Severe Acute Respiratory Syndrome Coronavirus 2,"N/A,Single Group Assignment,Diagnostic,None (Open Label),Technicians performing assays will be blinded to stage of the infection and outcomes","gender:All,Min Age:18 Years,Max Age:N/A",No,54
NCT04261907,Not yet recruiting,"February 7, 2020","June 30, 2020",2019-nCoV,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,160
NCT04428021,Not yet recruiting,"June 15, 2020","December 15, 2021",COVID-19,"Randomized,Parallel Assignment,Three arms randomized trial, partially blinded,Treatment,Triple (Participant, Care Provider, Outcomes Assessor),Only the two experimental arms are masked. COVID-19 convalescent plasma (CP) and standard plasma (SP) will be masked and delivered to the wards in identical bags; a tag printed as ""PLASMA TRIAL"" will cover the actual name of the product","gender:All,Min Age:18 Years,Max Age:N/A",No,180
NCT04360863,Recruiting,"April 24, 2020","June 30, 2020",Smoking Cessation,"Other,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:25 Years",No,150
NCT04324021,Recruiting,"April 2, 2020",December 2020,SARS-CoV-2,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:30 Years,Max Age:79 Years",No,54
NCT04384900,Recruiting,"May 11, 2020",December 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,150
NCT04376398,Recruiting,"April 6, 2020","September 30, 2020",COVID-19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:100 Years",No,200
NCT04357418,Completed,"April 1, 2020","June 30, 2020","Anxiety State,COVID-19,Isolation, Social,Health Personnel Attitude","Other,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,187
NCT04329650,Recruiting,"April 15, 2020","May 20, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04344379,Suspended,"April 17, 2020","July 15, 2020",SARS-CoV-2 Infection,"Randomized,Parallel Assignment,Prevention,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,122
NCT04351763,Recruiting,"April 27, 2020","April 10, 2021",COVID-19,"Randomized,Parallel Assignment,parallel group, randomized trial,Treatment,Single (Outcomes Assessor),Clinical events will be validated blindly by an independent clinical event committee (CEC) unaware of the treatment allocation.","gender:All,Min Age:18 Years,Max Age:99 Years",No,804
NCT04361123,Enrolling by invitation,"May 6, 2020",December 2021,"Coronavirus,COVID","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,450000
NCT04427137,Recruiting,"June 9, 2020",December 2022,Bipolar Depression,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04476823,Completed,"March 15, 2020","May 31, 2020",Clinical Practice During the COVID-19 Crisis,"Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,71
NCT04494867,Recruiting,"August 19, 2020",December 2020,Covid19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04351789,Recruiting,"May 1, 2020",April 2023,"COVID-19,Mental Health,Psychoeducation,Anxiety","Randomized,Parallel Assignment,Randomized 1:1 to either intervention group or control group,Prevention,Single (Outcomes Assessor),Due to the nature of the intervention, the RCT trial is not blinded, but the outcome measures are masked for health professionals and staff until the end of the study","gender:All,Min Age:18 Years,Max Age:N/A",No,66
NCT04425499,Not yet recruiting,June 2020,June 2020,"Advanced Suturing Skills,Surgical Education","Randomized,Parallel Assignment,Other,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04456088,Not yet recruiting,"July 15, 2020","December 15, 2020","COVID-19,SARS-CoV 2,Respiratory Disease,Pneumonia, Viral,Corona Virus Infection","Randomized,Parallel Assignment,This is a two phase study. The first 10 subjects will be treated with 80ppm NO; The remaining 40 subjects will be randomized in 1:1 ratio with subjects receiving 150 NO+SST or the SST alone.,Treatment,None (Open Label)","gender:All,Min Age:22 Years,Max Age:75 Years",No,50
NCT04388410,Recruiting,"August 25, 2020","December 31, 2020",COVID-19,"Randomized,Parallel Assignment,Randomized, double-blinded, multicenter, placebo-controlled study,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Encasement of plasma and saline bags with an identical material will be done in Blood bank","gender:All,Min Age:18 Years,Max Age:N/A",No,410
NCT04319445,Recruiting,"March 22, 2020",December 2020,"Migraine Disorders,Stress,Anxiety","N/A,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:N/A,Max Age:N/A",No,200
NCT04362358,Not yet recruiting,"May 1, 2020","October 1, 2021","Stress - Prevention of Sleep Disorders, PTSD and Depression","Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:70 Years",No,120
NCT04373044,Recruiting,"May 1, 2020","May 1, 2022",Symptomatic COVID-19 Infection Laboratory-Confirmed,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,144
NCT04425317,Recruiting,"June 24, 2020","June 15, 2021","Infertility,COVID,IVF","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:Female,Min Age:N/A,Max Age:45 Years",No,20
NCT04479202,Completed,"February 8, 2020","April 23, 2020","Berberine,COVID-19","Randomized,Parallel Assignment,Treatment,Double (Participant, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:80 Years",No,76
NCT04399356,Not yet recruiting,"October 12, 2020","February 12, 2021",COVID-19,"Randomized,Parallel Assignment,Double-blinded randomized controlled trial.,Treatment,Triple (Participant, Care Provider, Investigator),As all members of the Study Team will be blinded, Tufts Investigational Drug Services (IDS) will be unblinded and will dispense both the Niclosamide and placebo. The study intervention (Niclosamide) and placebo will be packaged and as indistinguishable as possible.","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04565080,Recruiting,"October 12, 2020","December 31, 2021","Parkinson's Disease,Functional Movement Disorders,COVID-19","Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,150
NCT04386564,"Active, not recruiting","May 15, 2020","November 15, 2020","COVID-19,Kidney Injury","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04371250,"Active, not recruiting","April 30, 2020","December 30, 2020","Resilience, Psychological,Loneliness,Youth,Surveys and Questionnaires","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:25 Years",No,800
NCT04476927,Not yet recruiting,"August 1, 2020","June 30, 2021",COVID-19,"N/A,Single Group Assignment,Total of 300 subjects - 200 suspected to COVID-19 and 100 healthy volunteers. all subjects will be undergo the DiaNose test.
For data analysis and algorithm building, subjects will be divided into one of the following study groups:
Group 1: Covid-19 infected suspected (up to 300 subjects)
Sub-Group A: Clinical symptomatic patients with positive Covid-19 test (positive PCR);
Sub-Group B: Asymptomatic patients with positive Covid-19 test (positive PCR)
Sub-Group C: Clinical symptomatic patients with negative Covid-19 test (negative PCR) Additional sub-groups may be added according to clinical symptoms.
Group 2: Healthy volunteers (up to 100 subjects),Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04391309,Not yet recruiting,July 2020,September 2021,SARS-CoV2,"Randomized,Parallel Assignment,Randomized, Double-Blind, Placebo-Controlled,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Placebo consists of identical-appearing diluent","gender:All,Min Age:18 Years,Max Age:N/A",Yes,300
NCT04472494,Not yet recruiting,"July 20, 2020","January 14, 2021","COVID-19,SARS-CoV-2","Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,129
NCT04295551,Not yet recruiting,"March 14, 2020","April 14, 2021",COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:100 Years",No,80
NCT04467931,"Active, not recruiting","January 19, 2020","July 31, 2020","Hypertension,COVID","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,10000
NCT04370886,Completed,"April 30, 2020","May 10, 2020",Blood Donation,"Randomized,Parallel Assignment,Health Services Research,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,456517
NCT04407130,Enrolling by invitation,"June 16, 2020",July 2020,COVID-19 Patients,"Randomized,Parallel Assignment,Randomized, Double-Blind, Placebo-Controlled Trial,Treatment,Double (Participant, Investigator)","gender:All,Min Age:40 Years,Max Age:65 Years",No,72
NCT04367857,Recruiting,"April 18, 2020",October 2021,"Covid-19,Coronavirus Infection,Coronavirus","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04492410,Recruiting,"July 21, 2020",March 2021,Cancer,"N/A,Single Group Assignment,Screening,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04370015,Not yet recruiting,"May 15, 2020","October 15, 2020","SARS-CoV-2,Healthcare Workers","Randomized,Parallel Assignment,parallel assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Double blinding","gender:All,Min Age:18 Years,Max Age:60 Years",No,374
NCT04483752,Recruiting,"June 8, 2020","November 8, 2021",CoV2 SARS Pneumonia,"N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04465695,Recruiting,"July 14, 2020","September 30, 2021",COVID-19,"Randomized,Parallel Assignment,Open-label randomised controlled trial,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,81
NCT04411147,Recruiting,"June 17, 2020","December 31, 2027",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,900
NCT04402840,Recruiting,"April 24, 2020",December 2020,"Acute Respiratory Distress Syndrome,COVID-19","N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,5
NCT04429555,Not yet recruiting,September 2020,"December 1, 2021","Pneumonia, Viral","Randomized,Parallel Assignment,Randomized, double-blind, placebo-controlled, parallel-group study.,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:80 Years",No,40
NCT04379154,Recruiting,"April 14, 2020","November 16, 2020",COVID-19,"N/A,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04398290,Withdrawn,"December 1, 2020","July 15, 2021","COVID-19,Hypoxemia,Hypoxemic Respiratory Failure","Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04443257,Enrolling by invitation,"July 8, 2020","July 25, 2021",Sars-CoV2,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04340921,Recruiting,"May 14, 2020","November 10, 2021","Cardiovascular Disease Acute,Cardiomyopathies,COVID","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,140
NCT04327674,Recruiting,"March 14, 2020","May 15, 2020",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,375
NCT04425213,Completed,"May 12, 2020","May 26, 2020","COVID,Severe Acute Respiratory Syndrome,Obesity,Comorbidities and Coexisting Conditions","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,250
NCT04488575,Recruiting,"August 26, 2020","December 21, 2020",Covid19,"Randomized,Parallel Assignment,Patients will be randomized to either the active (EDP1815) or placebo group (1:1 randomization), in addition to standard of care. Dosing will be initiated on a twice daily regime for the first 3 days (6 doses) and then once daily for the remaining 11 days (14 days total treatment course).,Treatment,Triple (Participant, Investigator, Outcomes Assessor),Fully blinded to the participants, investigator, and sponsor","gender:All,Min Age:18 Years,Max Age:N/A",N/A,60
NCT04360876,Not yet recruiting,"September 1, 2020","January 30, 2021","COVID-19,ARDS","Randomized,Parallel Assignment,Single-center, Phase 2a, pragmatic, randomized, double-blinded, placebo-controlled,Treatment,Double (Participant, Care Provider),Participants confirmed to meet all eligibility criteria who have provided informed consent will be randomized 1:1 to dexamethasone versus placebo. A randomized group assignment will be provided to the investigator or research assistant. Randomization will be performed according to a central randomization scheme and will stratified by site in permuted blocks of varying size.","gender:All,Min Age:18 Years,Max Age:N/A",No,90
NCT04343690,Withdrawn,"March 27, 2020","May 1, 2020",COVID-19,"N/A,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04296643,Not yet recruiting,"April 1, 2020","January 1, 2021","Coronavirus,N95,Medical Mask","Randomized,Parallel Assignment,Prevention,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,576
NCT04490239,Not yet recruiting,August 2020,September 2020,Covid19,"Sequential Assignment,This study will evaluate the acute and multi-day (14 days) tolerability of intranasally administered heparin. Two doses will be tested in the acute phase: 1000 U/day, then 2000 U/day. In the multi-day phase, the highest tolerated dose from the acute phase will be tested over a 14-day period of daily self-administration.,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,6
NCT04445376,Completed,"July 3, 2020","October 3, 2020",Covid19,"Non-Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:75 Years",No,20
NCT04360980,Recruiting,"March 20, 2020","September 30, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04328285,"Active, not recruiting","April 14, 2020","November 30, 2020",COVID-19,"Randomized,Parallel Assignment,A randomized double-blind placebo-controlled clinical trial,Prevention,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,1200
NCT04394117,Recruiting,"June 19, 2020","April 30, 2021","SARS-Cov-2,COVID-19","Randomized,Parallel Assignment,CLARITY is a randomised control trial of two parallel groups;
Standard Care + Angiotensin Receptor Blocker (ARB)
Standard Care
Participants will be randomised in a 1:1 ratio. Randomisation will be stratified according to whether the participant is planned for hospital admission or home-based care.,Treatment,Single (Outcomes Assessor),Trial Statistician and sponsor staff will remain blinded to treatment allocation throughout the trial.","gender:All,Min Age:18 Years,Max Age:N/A",No,605
NCT04351152,Recruiting,"April 30, 2020",September 2020,Coronavirus Disease 2019 (COVID-19) Pneumonia,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator),Double-Blind","gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04501783,"Active, not recruiting","May 20, 2020",August 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,168
NCT04541979,Recruiting,"June 4, 2020","December 1, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04366908,Not yet recruiting,"April 28, 2020","August 28, 2020","SARS-CoV 2,COVID19,SARS (Severe Acute Respiratory Syndrome),Cytokine Release Syndrome,Cytokine Storm","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:90 Years",No,1008
NCT04481360,Not yet recruiting,August 2020,September 2021,Coronavirus,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:99 Years",No,100
NCT04416360,Recruiting,"May 5, 2020",January 2021,"Autism Spectrum Disorder,Attention-deficit Hyperactivity Disorder","N/A,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:6 Years,Max Age:17 Years",No,40
NCT04368676,Recruiting,"June 25, 2020","June 30, 2021","Job Stress,Workplace Stress,Compassion Fatigue,Psychological Trauma,Healthcare Workers,Healthcare Providers","Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor),Participants will be blinded to the treatment hypothesis wand the data analyst will be blinded to treatment allocation.","gender:All,Min Age:18 Years,Max Age:70 Years",No,60
NCT04474496,Enrolling by invitation,"July 27, 2020","November 1, 2020",COVID-19,"Other,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2000
NCT04423770,"Active, not recruiting","June 8, 2020","June 8, 2021",Severe Acute Respiratory Syndrome Coronavirus 2,"Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04412304,Completed,"March 6, 2020","May 28, 2020","Covid-19,Thromboembolic Events,Bleeding","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,166
NCT04363060,Not yet recruiting,"April 30, 2020","July 30, 2020",COVID-19 Pneumonia,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:99 Years",No,104
NCT04510207,Recruiting,"July 16, 2020","September 16, 2021",COVID-19,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,45000
NCT04409509,Recruiting,"July 1, 2020",December 2020,Coronavirus Disease 2019 (COVID-19),"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,124
NCT04347538,Recruiting,"May 1, 2020",June 2022,COVID 19,"Randomized,Parallel Assignment,Patients enrolled will be randomized to one of three treatment groups (1. control- no intervention, 2. intervention 1 - nasal saline irrigations BID, 3. intervention 2- nasal saline irrigations with ½ teaspoon surfactant (Johnson's baby shampoo) BID).,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,90
NCT04351516,Recruiting,"April 21, 2020","May 1, 2021","SARS-CoV 2,COVID-19","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:65 Years,Max Age:N/A",No,350
NCT04366765,Recruiting,"March 19, 2020","June 30, 2021","COVID-19,SARS-CoV 2","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1500
NCT04344561,Recruiting,"May 25, 2020","May 1, 2021","COVID,Hypoxic Respiratory Failure","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,70
NCT04405843,Recruiting,"July 14, 2020","December 14, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04425031,Recruiting,"August 25, 2020","March 1, 2024","Hypoxemic Respiratory Failure,Oxygen Toxicity","Randomized,Parallel Assignment,Prevention,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,780
NCT04355871,Completed,"March 18, 2020","April 17, 2020",Covid19,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,4035
NCT04387955,Not yet recruiting,May 2020,June 2021,"COVID-19,Chilblains","N/A,Single Group Assignment,Prospective Cohort,Diagnostic,None (Open Label)","gender:All,Min Age:12 Years,Max Age:N/A",No,30
NCT04452604,Not yet recruiting,"August 1, 2020","December 1, 2023","Acute Myeloblastic Leukemia,Acute Lymphoblastic Leukemia,SARS-CoV-2","Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04344925,Recruiting,"April 18, 2020",December 2020,COVID-19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04397497,Not yet recruiting,"May 22, 2020","November 22, 2020","Covid-19,Acute Respiratory Failure,ARDS, Human,Sars-CoV2,Viral Pneumonia","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04541485,Not yet recruiting,"October 6, 2020","January 29, 2021",COVID-19 Patients,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:65 Years",No,40
NCT04570501,Not yet recruiting,November 2020,May 2021,Covid19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,160
NCT04505631,Recruiting,"June 10, 2020",June 2021,"Covid19,Dyspnea","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04466800,Recruiting,"July 30, 2020","August 13, 2021",COVID,"Randomized,Parallel Assignment,Multicenter, randomized, comparative, parallel-group trial,Supportive Care,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,160
NCT04452669,Not yet recruiting,"August 15, 2020","February 1, 2021",COVID-19,"Randomized,Parallel Assignment,Double-blind, placebo controlled study comparing study treatment group to placebo controls who received SOC,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Placebo controlled","gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04524754,Recruiting,"July 11, 2020","November 30, 2020",Anosmia,"Case-Only,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,218
NCT04529447,Completed,"June 10, 2020","August 10, 2020",Covid19,"Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,485
NCT04395911,Recruiting,"September 10, 2020",December 2021,"AKI,ARDS,COVID","N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,35
NCT04535154,"Active, not recruiting","March 31, 2020","June 1, 2022","Covid19,Lung Function Decreased","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,264
NCT04512027,Recruiting,"September 15, 2020","October 16, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:45 Years",No,10
NCT04333251,Not yet recruiting,"April 1, 2020","December 31, 2022","Pneumonia, Interstitial","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,115
NCT04419610,Not yet recruiting,September 2020,March 2021,COVID,"Randomized,Single Group Assignment,Health Services Research,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,60
NCT04432298,Recruiting,"June 20, 2020",January 2021,COVID-19,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:40 Years,Max Age:85 Years",No,130
NCT04383587,Completed,"May 6, 2020","July 31, 2020","SARS-CoV 2,COVID-19","N/A,Single Group Assignment,Health Services Research,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04480112,Enrolling by invitation,"June 2, 2020",May 2021,"Memory Disorders,Alzheimer Disease,Mild Cognitive Impairment","Non-Randomized,Crossover Assignment,The investigators will employ an AB/BA crossover design (2-sequence, 2-period, 2-treatment design) where A will be the intervention phase and B will be the passive control phase. Each period will have a duration of 1 month. Assessment of the primary outcome will be done at the end of each period. Since this is a study of a behavioral intervention, 4-week washout period will suffice to observe an acute change in cognitive performance without significant carryover effects.
To avoid imbalance among groups, randomization will be stratified by cognitive syndrome diagnosis (healthy older adult, mild cognitive impairment and mild dementia). Participants will be randomized to the treatment sequences using a 1:1 allocation ratio.,Other,Single (Outcomes Assessor),Trial investigators and outcome assessors will be blind to the treatment randomization and allocation..","gender:All,Min Age:N/A,Max Age:N/A",No,150
NCT04513847,Not yet recruiting,"August 13, 2020","October 13, 2020","Psoriasis,Covid19","Case-Control,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1000
NCT04363866,Not yet recruiting,May 2020,June 2021,"COVID-19,SARS-CoV-2","Randomized,Parallel Assignment,Treatment,Single (Participant),While participants will be blinded to the study intervention, study staff will be aware of treatment assignment.","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04359602,Recruiting,"April 8, 2020","April 20, 2042",Recovered From COVID-19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,10000
NCT04356833,Recruiting,"April 22, 2020","January 14, 2021",COVID,"Non-Randomized,Sequential Assignment,phase II, open label, single centre, uncontrolled, repeated dose, pilot trial,Treatment,None (Open Label)","gender:All,Min Age:16 Years,Max Age:70 Years",No,24
NCT04420299,Recruiting,"June 4, 2020","March 31, 2021",Covid-19,"Randomized,Parallel Assignment,randomized, single-blind, parallel control group,Treatment,Single (Participant),Subjects will be blinded to the dosing regimen (treatment dose or prophylactic dose).","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04530617,Not yet recruiting,September 2020,February 2021,"Covid19,Diabetes,Hypertension,Obesity","Randomized,Parallel Assignment,A randomized, placebo-controlled, parallel, multicenter, multi-arm, phase II trial of novel agents for treatment of high-risk COVID-19 positive outpatients. Subjects who meet the inclusion/exclusion criteria and have properly signed the informed consent will be randomized to the test group or placebo group in the ratio of 1:1:1:1.,Treatment,Triple (Participant, Care Provider, Investigator),The masking of the protocol will be maintained throughout the duration of the study. This will be done with the use of a matched placebo and a non-continuous coding (tablets in the case of camostat and tea bags/coffer for Artemisia) that has the same description and dose as the interventions so that both, the investigators and the patient does not know the treatment assignment.","gender:All,Min Age:18 Years,Max Age:N/A",No,360
NCT04387890,Not yet recruiting,"June 1, 2020","August 31, 2020","COVID-19,SARS-CoV 2,Health Personnel","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04383444,Recruiting,"July 7, 2020","August 1, 2023",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1050
NCT04487769,Recruiting,"June 1, 2020",October 2020,"Covid19,Ultrasound,ARDS","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT03963622,Not yet recruiting,July 2020,July 2022,ARDS,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,370
NCT04360707,Recruiting,"April 8, 2020","April 8, 2021",SARS-CoV-2,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:1 Year,Max Age:N/A",No,300
NCT04333654,Terminated,"April 12, 2020","May 26, 2020",Coronavirus Infection,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:80 Years",No,8
NCT04365257,Recruiting,"May 13, 2020",December 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:45 Years,Max Age:85 Years",No,220
NCT04364984,Recruiting,"April 1, 2020","August 1, 2021","Hypertension,COVID-19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:90 Years",No,10
NCT04328012,Recruiting,"April 6, 2020","April 1, 2021",SARS-CoV-2 Infection,"Randomized,Parallel Assignment,randomized, double blind, placebo controlled clinical trial,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04397575,Recruiting,"April 3, 2020","September 1, 2020","Cancer,COVID,Solid Tumor,Social Inequality,French National Cohort,Chemotherapy,Immunotherapy,Surgery,Radiotherapy","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04393051,Not yet recruiting,"May 20, 2020","July 30, 2020","Covid-19,SARS-CoV 2,SARS Pneumonia","Randomized,Parallel Assignment,Phase II randomized clinical trial to evaluate the efficacy and safety of baricitinib in patients with SARS-CoV2 pneumonia,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,126
NCT04375137,Recruiting,"April 20, 2020","September 30, 2020",Oxidative Stress,"Case-Control,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,90
NCT04483908,Recruiting,"April 10, 2020","May 30, 2022",COVID-19 Infection,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,550
NCT04444609,Recruiting,"June 18, 2020",June 2022,"COVID-19,SARS-CoV 2,ARDS, Human,Immune System Disorder","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:16 Years,Max Age:N/A",No,230
NCT04568018,Recruiting,"July 3, 2020",December 2021,ARDS Due to COVID-19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:75 Years",No,120
NCT04368390,Recruiting,"April 3, 2020",April 2021,Covid-19,"Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04529421,Not yet recruiting,September 2020,December 2020,"Infection,Infection Control","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,70000
NCT04321928,Recruiting,"April 1, 2020","August 21, 2021","SARS-CoV-2,Coronavirus,COVID-19,2019-nCoV,2019nCoV","Randomized,Parallel Assignment,This is a randomized controlled, adaptive, two-arm, parallel trial. The target patient population consists of adults age above 60 years without confirmed COVID-19 infection or current hospitalization. The sample size calculation suggests that 7576 subjects (3788/ each arm) are required. The allocation ratio is 1:1. Eligible participants in the generalized health education intervention arm will receive healthy lifestyle advice according to World Health Organization (WHO) principles. On the personalized education arm, participants will receive detailed informative intervention regarding lifestyle changes based on their current habits.,Prevention,Double (Participant, Outcomes Assessor),Subjects will be blinded to knowledge of the details of differences between the interventions.
Everyone else (outcome assessors, caregivers and data analysts) will be blinded regarding the allocation.","gender:All,Min Age:60 Years,Max Age:N/A",No,7576
NCT04516928,Recruiting,"September 21, 2020","November 2, 2020","SARS-CoV Infection,Covid19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,950
NCT04404244,Recruiting,"January 1, 2020","June 1, 2021",Coronavirus COVID-19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:18 Years",No,100
NCT04368832,"Active, not recruiting","April 25, 2020","September 30, 2021","Pregnancy Related,COVID","Other,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,108
NCT04573322,Recruiting,"September 10, 2020","December 14, 2021",SARS-CoV-2 (Covid19),"Randomized,Parallel Assignment,Open-label, pharmacokinetic, pharmacodynamic, ascending dose, safety and tolerability lead-in Single-center, randomized, placebo-controlled, double-blind, adaptive, safety and efficacy pilot,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Lead-in: no masking. Randomized pilot: The participants, care providers, investigators, and outcomes assessors are masked. The pharmacist, unblinded clinical research associate, and unblinded study drug administrator are not masked.","gender:All,Min Age:18 Years,Max Age:N/A",No,224
NCT04456595,Recruiting,"July 21, 2020",October 2021,COVID-19,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,8870
NCT04475575,Completed,"April 6, 2020","July 1, 2020","SARS-CoV Infection,Covid19","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,222
NCT04362124,Not yet recruiting,April 2020,November 2021,COVID-19,"Randomized,Parallel Assignment,A multicenter, double-blind, randomized, phase III clinical trial, divided into two groups (vaccine and placebo) using a 1: 1 allocation ratio.
The treatment allocation will be performed according to random code.,Supportive Care,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Double-blind trial. The blinding of the investigational vaccine will be maintained using an opaque label for the two products (vaccine and placebo).
The subjects, who collect the data (e.g., investigator and coordinator) and who evaluate the data (e.g., statistician) will be blinded. One or more pharmacists/vaccine administrators designated from the facility will not be blinded. These designated unblinded individuals will maintain the blindness of the investigational vaccine and will not be involved in evaluating the safety of the subjects.","gender:All,Min Age:18 Years,Max Age:65 Years",No,1000
NCT04477642,Withdrawn,August 2020,December 2020,COVID-19,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04364022,Recruiting,"April 23, 2020",March 2021,Prevention of COVID-19,"Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:16 Years,Max Age:N/A",No,300
NCT04400799,Recruiting,"June 15, 2020","April 14, 2021","COVID-19,Pulmonary Embolism, Deep Vein Thrombosis","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:50 Years,Max Age:N/A",No,1000
NCT04377464,Not yet recruiting,"May 5, 2020","April 30, 2022","COVID-19,Quality of Life","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04374643,Recruiting,"April 1, 2020","November 1, 2020","Depression,COVID 19","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04384471,Enrolling by invitation,"April 29, 2020","January 1, 2021","Type1diabetes,Covid19","Case-Only,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:1 Year,Max Age:N/A",No,384
NCT04534595,Recruiting,"April 30, 2019",March 2021,COVID-19 Experience,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:4 Years,Max Age:13 Years",No,1500
NCT04359316,Not yet recruiting,"April 20, 2020","May 5, 2020",COVID-19,"Randomized,Parallel Assignment,The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04395170,Not yet recruiting,September 2020,June 2021,Coronavirus Disease 2019 (COVID-19),"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,75
NCT04450004,"Active, not recruiting","July 10, 2020","April 30, 2021",SARS-CoV 2,"Randomized,Sequential Assignment,Prevention,None (Open Label),Partially-blinded","gender:All,Min Age:18 Years,Max Age:55 Years",No,180
NCT04359277,Terminated,"April 21, 2020","September 20, 2020",COVID-19,"Randomized,Parallel Assignment,The proposed study is designed as an open label randomized trial of patients hospitalized COVID-19 positive patients with an elevated D-dimer. Patients will be randomized to higher-dose (e.g. therapeutic) anticoagulation versus lower-dose (e.g. prophylactic) anticoagulation in 1:1 ratio.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,77
NCT04385771,Not yet recruiting,"June 1, 2020","October 31, 2021","Coronavirus Infection,COVID,SARS-CoV 2,Respiratory Failure,Cytokine Storm,Extracorporeal Membrane Oxygenation","Randomized,Parallel Assignment,randomized controlled trial examining COVID-patients requiring vv-ECMO therapy (+/- cytokine adsorption),Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:100 Years",No,80
NCT04403880,Recruiting,"May 13, 2020",August 2021,"SARS-CoV-2,COVID-19","Cohort,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,727
NCT04372082,Not yet recruiting,May 2020,May 2023,Sars-CoV2,"Randomized,Parallel Assignment,Treatment,Single (Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,480
NCT04436471,Completed,"June 17, 2020","August 10, 2020",Preventive Immunization COVID-19,"Non-Randomized,Parallel Assignment,An open, prospective, two-stage, non-randomized, first-phase study involving healthy volunteers,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,38
NCT04435275,Not yet recruiting,"June 30, 2020","May 1, 2021",COVID-19,"Randomized,Crossover Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,50
NCT04407585,Recruiting,"June 1, 2020","May 10, 2021",Covid-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1000000
NCT04353583,Recruiting,"April 21, 2020","March 31, 2021","Acute Kidney Injury,Corona Virus Infection","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04363502,Recruiting,"May 7, 2020",December 2020,Covid19,"Randomized,Parallel Assignment,This is a randomized, double-blind, placebo-controlled, design. We propose the administration of an investigational drug in patients with high predicted short-term mortality secondary to COVID-19 disease. 30 Patients will be randomly assigned in a 1:1 ratio to two study arms that will receive clazakizumab at a dose of 25 mg or placebo.,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:100 Years",No,30
NCT04527575,"Active, not recruiting","July 27, 2020","October 4, 2020",Covid19,"Randomized,Parallel Assignment,A simple, blind, placebo-controlled, randomized study involving healthy volunteers,Prevention,Single (Participant),Masking in Phase 2","gender:All,Min Age:18 Years,Max Age:60 Years",No,100
NCT04432805,Recruiting,"June 15, 2020","June 15, 2021",Pregnant Women Suspected of COVID-19,"N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:Female,Min Age:18 Years,Max Age:N/A",No,160
NCT04425733,Withdrawn,"July 7, 2020","November 10, 2020","Coronavirus Disease 2019 (COVID-19),Pneumonia,Hypoxemia","Randomized,Sequential Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:80 Years",No,0
NCT04357366,Recruiting,"April 15, 2020","April 15, 2022","COVID-19,Virus Diseases,Corona Virus Infection,Lower Respiratory Tract Infection Viral","N/A,Single Group Assignment,Treatment with anakinra and trimethoprim/sulfamethoxazole,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04403685,Terminated,"May 8, 2020","July 21, 2020","COVID,SARS Pneumonia,Cytokine Release Syndrome","Randomized,Parallel Assignment,Prospective, randomized, superiority, open-label, controlled trial. Randomization 1:1 to best supportive care (BSC) versus Tocilizumab + BSC,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,129
NCT04551547,Not yet recruiting,"September 28, 2020",September 2021,COVID-19,"Randomized,Parallel Assignment,Prevention,Double (Participant, Investigator)","gender:All,Min Age:3 Years,Max Age:17 Years",No,552
NCT04497402,Not yet recruiting,"September 1, 2020","June 1, 2022",Covid19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,88
NCT04331795,Completed,"April 4, 2020","June 5, 2020",COVID-19,"Non-Randomized,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,32
NCT04417257,Recruiting,"June 29, 2020","January 15, 2021",COVID-19 Disease,"Randomized,Parallel Assignment,Double-blind, randomized, parallel groups and placebo-controlled trial,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Patients will be randomly assigned to take either the active drug (LAU-7b capsule) or a matching inactive placebo (inactive capsule)","gender:All,Min Age:45 Years,Max Age:N/A",No,240
NCT04409535,"Active, not recruiting","May 7, 2020","March 31, 2021","Activities,Mental Health Issue,Life Style","Ecologic or Community,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:85 Years",No,500
NCT04352517,Recruiting,"March 16, 2020","September 30, 2020","Sedentary Behavior,Mental Health Wellness 1","Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,3500
NCT04489628,Not yet recruiting,"August 1, 2020","August 1, 2021",SARS-CoV Infection,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,110
NCT04360096,Not yet recruiting,"July 1, 2020","November 30, 2020","SARS-CoV 2,COVID,ARDS,ALI,Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS),Dyspnea","Randomized,Parallel Assignment,Multicenter Randomized Placebo-controlled Trial,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Only the study pharmacist will be aware of treatment assignment","gender:All,Min Age:12 Years,Max Age:85 Years",No,288
NCT04462757,"Active, not recruiting","May 28, 2020","September 30, 2020",COVID-19,"Randomized,Parallel Assignment,Patients will be randomly assigned to one of two arms:-
Subcutaneous arm: 100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.
Intravenous arm: 100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours.,Health Services Research,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,5
NCT04372979,Not yet recruiting,May 2020,May 2021,COVID-19,"Randomized,Parallel Assignment,Treatment,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:80 Years",No,80
NCT04468581,"Active, not recruiting","March 8, 2020","July 31, 2020",Coronavirus,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:21 Years,Max Age:N/A",No,500
NCT04404270,Recruiting,"May 26, 2020",February 2021,Sars-CoV2,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2500
NCT04458948,"Active, not recruiting","March 24, 2020","March 24, 2025",COVID-19,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,10000
NCT04349631,Enrolling by invitation,"April 22, 2020","December 31, 2020",COVID-19,"N/A,Single Group Assignment,Prevention,None (Open Label)","gender:All,Min Age:N/A,Max Age:N/A",N/A,56
NCT04449081,Completed,"April 25, 2020","June 20, 2020","Acute Respiratory Distress Syndrome,Corona Virus Infection,Acute Lung Injury,Fever,Myalgia,Cough,Dyspnea,Septic Shock,Bleeding","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:30 Years",No,215
NCT04374461,Recruiting,"May 1, 2020",May 2021,Covid-19,"Non-Randomized,Parallel Assignment,This is a single-institution study that will be open at MSKCC's Manhattan campus. Patients will be enrolled into 2 separate arms. The mechanically ventilated &/or managed in a critical-care arm is closed to accrual as of September 2020.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,84
NCT04327401,Terminated,"April 13, 2020","July 22, 2020","Coronavirus Infection,Pneumonia, Viral,Acute Respiratory Distress Syndrome","Randomized,Parallel Assignment,Dexamethasone. After randomization, dexamethasone 20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days + standard treatment (according to the treatment protocol for 2019-nCoV infection).
Standard treatment (according to the treatment protocol for 2019-nCoV infection).,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,299
NCT04408235,Not yet recruiting,June 2020,June 2021,"COVID,Pneumonia, Viral,Coagulation Disorder","Randomized,Parallel Assignment,This is a multicentre, randomised controlled, open label, investigator sponsored, two arms study.,Treatment,Single (Investigator),Randomisation will be centrally performed by using a secure, web-based system, which will be developed by the Methodological and Statistical Unit at the Azienda Ospedaliero-Universitaria of Modena. Randomisation stratified by 4 factors: 1) Gender (M/F); 2) Age (<75/≥75 years); 3) BMI (<30/≥30); 4) Co-morbidities (0-1/>2) with random variable block sizes will be generated by STATA software. The web-based system will guarantee the allocation concealment.","gender:All,Min Age:18 Years,Max Age:80 Years",No,300
NCT04429529,"Active, not recruiting","June 9, 2020",February 2021,Coronavirus Disease-2019 (COVID-19),"Randomized,Parallel Assignment,Participants are assigned to either treatment or placebo,Treatment,Double (Participant, Investigator)","gender:All,Min Age:21 Years,Max Age:50 Years",No,32
NCT04323644,Recruiting,"January 1, 2020","September 30, 2020","COVID-19,Coronavirus,Surgery","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1000
NCT04460703,Completed,"July 3, 2020","July 8, 2020","Vaccination,COVID-19","Randomized,Parallel Assignment,In this study, 2/15 of participants will be assigned to a control message (bird feeding passage), 3/15 of sample to a baseline vaccine message, and 1/15 to each of the 10 other treatment arms.,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04546191,Completed,"July 1, 2020","September 1, 2020",Covid19,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1580
NCT04363333,"Active, not recruiting","April 27, 2020","December 31, 2020","COVID,Obstructive Sleep Apnea,Pneumonia","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,320
NCT04344665,"Active, not recruiting","April 23, 2020",January 2021,"Surgery,Perioperative Complication,COVID","Randomized,Parallel Assignment,Prevention,Single (Outcomes Assessor)","gender:All,Min Age:40 Years,Max Age:N/A",No,905
NCT04376814,Completed,"March 29, 2020","May 25, 2020","COVID-19,Favipiravir,Kaletra,Hydroxychloroquine,Lopinavir/Ritonavir","Non-Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:16 Years,Max Age:100 Years",No,40
NCT04475302,Recruiting,"July 1, 2020",May 2021,COVID,"Non-Randomized,Single Group Assignment,In this study, as we are employing a control group that is not vaccinated against the disease to be prevented, but some clinical data are available to support the likely efficacy of the candidate vaccine, we will use unbalanced randomization and enrol participants to control group in the ratio of 2:1, so that majority of the study participant will receive the vaccine,Prevention,None (Open Label)","gender:All,Min Age:60 Years,Max Age:80 Years",No,2175
NCT04452773,Recruiting,"July 14, 2020",December 2021,COVID19,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,315
NCT04403035,Recruiting,"May 10, 2020","May 9, 2021",Covid-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:95 Years",No,100
NCT04412460,Recruiting,"March 20, 2020","December 31, 2021","COVID,ARDS, Human","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04330638,Recruiting,"April 3, 2020",December 2020,COVID-19,"Randomized,Factorial Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,342
NCT04367545,Recruiting,"April 16, 2020",July 2020,"COVID,RT-ddPCR Multiplex","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04276688,Completed,"February 10, 2020","March 31, 2020",Novel Coronavirus Infection,"Randomized,Parallel Assignment,open-label randomised controlled trial,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,127
NCT04573764,Not yet recruiting,"October 1, 2020","January 1, 2022",COVID-19,"Randomized,Crossover Assignment,Randomized placebo-controlled double-blinded crossed-over acute intervention study.,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,12
NCT04434144,Completed,"May 2, 2020","June 5, 2020","Ivermectin,Hydroxychloroquine,COVID19","Case-Only,Prospective","sampling_method:Probability Sample,gender:All,Min Age:16 Years,Max Age:80 Years",No,116
NCT04447469,Recruiting,"July 27, 2020",April 2021,COVID,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,573
NCT04302766,Available,N/A,N/A,N/A,N/A,"gender:All,Min Age:N/A,Max Age:N/A",N/A,N/A
NCT04390022,"Active, not recruiting","July 31, 2020","December 30, 2020","Covid-19,Coronavirus Infection,SARS-CoV-2 Infection","Randomized,Parallel Assignment,SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.,Treatment,Double (Participant, Investigator),Double blind","gender:All,Min Age:18 Years,Max Age:59 Years",No,24
NCT04358380,Enrolling by invitation,"April 15, 2020","December 31, 2020",Liver Injury,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:17 Years,Max Age:N/A",No,320
NCT04559035,Enrolling by invitation,"September 24, 2020","December 31, 2020",Covid19,"Randomized,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:55 Years,Max Age:N/A",No,200
NCT04558476,Recruiting,"September 1, 2020","September 1, 2022","Covid19,Mechanical Ventilation Complication,Corona Virus Infection,Respiratory Failure,SARS (Severe Acute Respiratory Syndrome)","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04542993,Not yet recruiting,September 2020,June 2022,"Covid19,SARS-CoV Infection","Randomized,Single Group Assignment,Placebo controlled Resveratrol and Zinc combination therapy,Supportive Care,Single (Participant),single blinded","gender:All,Min Age:18 Years,Max Age:75 Years",No,60
NCT02788903,"Active, not recruiting",March 2016,February 2021,"Obesity,Diabetes,Covid19","Cohort,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2000000
NCT04453371,Not yet recruiting,"October 15, 2020","February 15, 2021",Acute Respiratory Distress Syndrome,"Randomized,Parallel Assignment,Treatment,Double (Participant, Care Provider)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04368013,Not yet recruiting,"April 28, 2020","April 14, 2026",COVID-19,"N/A,Single Group Assignment,Screening,None (Open Label)","gender:All,Min Age:15 Years,Max Age:100 Years",No,400
NCT04365231,Not yet recruiting,April 2020,January 2021,COVID19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:Female,Min Age:18 Years,Max Age:N/A",No,50
NCT04357496,Not yet recruiting,"April 20, 2020","October 30, 2020","Fever,Pneumonia,Cough","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:60 Years,Max Age:N/A",No,400
NCT04441710,Not yet recruiting,July 2020,January 2022,COVID,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,2500
NCT04330300,Suspended,"April 30, 2020","December 1, 2021","Hypertension,COVID-19","Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:60 Years,Max Age:N/A",No,2414
NCT04537208,Recruiting,"September 3, 2020",October 2021,COVID-19 (Healthy Volunteers),"Randomized,Parallel Assignment,This is a parallel group prevention study. Participants from 2 age groups (adults 18 through 49 years of age and adults 50 years of age and older) will receive either 1 injection (Cohort 1) or 2 injections (Cohort 2) of study vaccine or placebo control.
As a precautionary step, a sentinel safety cohort of 6 participants (younger adults only) within each dosing group from Cohort 1 will be enrolled. An early safety data review will be performed, including evaluation of safety data and laboratory measures to Day 9. Upon acceptable safety demonstrated from unblinded data review by limited members of the Sponsor Study Team, the remaining participants will be enrolled simultaneously.,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Participants, outcome assessors, Investigators, laboratory personnel, and the majority of Sponsor study staff will be blinded to vaccine group assignment; injection schedule will be unblinded and those preparing/administering the study interventions will be unblinded.","gender:All,Min Age:18 Years,Max Age:N/A",No,440
NCT04442165,Not yet recruiting,"July 15, 2020","July 14, 2021",COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,15393
NCT04461379,Recruiting,"July 21, 2020","January 1, 2021","BCG,COVID-19,SARS-CoV2,Corona Virus Infection","Randomized,Parallel Assignment,A randomized double-blinded clinical trial, using computer software, participants will be allocated between two groups:
Intervention: BCG vaccine intradermally 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis. (Tokio 172 strain). The application technique is based on the National Vaccination Manual version 2017.
Comparator: Placebo, intradermally 0.1 ml of NaCl 0.9%,Prevention,Triple (Participant, Care Provider, Outcomes Assessor),Participants, researchers (including members of the research team that will assess outcomes), and treating physicians or health personnel (should the patient require in-hospital management) will be blinded to the treatment group to which the patients were randomized. Only the personnel who apply the vaccine will not be blinded to the treatment group to which the patients were randomized (this personnel will not have any further contact with the patients or provide any other type of patient care).","gender:All,Min Age:18 Years,Max Age:N/A",No,908
NCT04424355,Recruiting,"May 19, 2020","June 20, 2021","Coronavirus Infections,Pneumonia","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,115
NCT04348448,Not yet recruiting,April 2020,September 2020,COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,100
NCT04422626,Not yet recruiting,"July 1, 2020","December 1, 2022","SARS-CoV-2,COVID-19","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,42
NCT04472559,Not yet recruiting,"July 25, 2020","February 25, 2021","Quality of Life,Stress","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04544176,"Active, not recruiting","January 1, 2020","January 1, 2021",Covid19,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:16 Years,Max Age:100 Years",No,34000
NCT04449978,Recruiting,"April 9, 2020","December 31, 2022","Coronavirus,COVID-19,Virus,Family and Household,Infection Viral","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:10 Years",No,1082
NCT04507867,Not yet recruiting,August 2020,December 2020,"Covid19,Diabetes Mellitus,Hypertension,Obesity","Randomized,Sequential Assignment,Supportive Care,Single (Investigator)","gender:All,Min Age:30 Years,Max Age:75 Years",No,240
NCT04342650,Completed,"April 8, 2020","June 8, 2020","COVID-19,SARS-CoV Infection,Severe Acute Respiratory Syndrome (SARS) Pneumonia,Clinical Trial","Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,152
NCT04388436,"Active, not recruiting","May 11, 2020","October 10, 2021",COVID,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04381377,Recruiting,"April 29, 2020",April 2021,"Infections, Coronavirus","Randomized,Parallel Assignment,Treatment,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:85 Years",No,394
NCT04417374,Completed,"May 1, 2020","June 30, 2020","COVID 19,Disease Outbreak,Mental Disorders","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,94
NCT04369300,Recruiting,"April 24, 2020","February 24, 2021",COVID-19,"Other,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:90 Years",No,1000
NCT04399798,Not yet recruiting,"May 15, 2020","November 15, 2020",Corona Virus Infection,"N/A,Single Group Assignment,Proof-of-concept trial with an exploratory single-arm proof of concept Phase IIa study,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:74 Years",No,13
NCT04375202,Recruiting,"April 18, 2020","October 31, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,308
NCT04367740,Enrolling by invitation,"April 28, 2020",April 2021,"Asymptomatic Condition,Infection Viral,Coronavirus Infections,Severe Acute Respiratory Syndrome Coronavirus 2,Coronaviridae Infections,RNA Virus Infections,Virus Diseases,Communicable Disease","Case-Only,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:99 Years",No,10000
NCT04279899,Recruiting,"February 1, 2020","December 31, 2020","Neonatal Infection,Perinatal Problems,Infectious Disease","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:28 Days",No,100
NCT04371354,Recruiting,"April 27, 2020","July 27, 2020","Covid-19 Disease,Endoscopy Unit","Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04368208,Recruiting,"April 29, 2020","December 14, 2020",Postnatal Depression,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:50 Years",No,900
NCT04425005,Recruiting,"May 10, 2020",February 2021,"Bariatric Surgery,Obesity","Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:80 Years",No,70
NCT04344119,Recruiting,"April 9, 2020","June 30, 2020","Skin Manifestations,COVID,Chilblains","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:90 Years",No,30
NCT04402905,Recruiting,"June 15, 2020","August 15, 2020",Coronavirus Infection,"Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,450
NCT04373161,Completed,"March 20, 2020","April 22, 2020","Sars-CoV2,COVID-19,COVID","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,209
NCT04506515,Completed,"April 9, 2020","April 30, 2020","Covid19,Stress, Psychological,Work Related Stress,Epidemic Disease,SARS-CoV Infection","Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:70 Years",No,3000
NCT04394078,Completed,"May 6, 2020","May 18, 2020","Depression,Quality of Life,Covid 19,Social Isolation","Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:15 Years,Max Age:65 Years",No,543
NCT04386551,Recruiting,"May 11, 2020",December 2020,"Sars-CoV2,RT-PCR,Saliva Collection,Nasopharyngeal Sample","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,225
NCT04395781,Recruiting,"May 18, 2020","December 31, 2023","COVID,Pediatric Disorder","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:21 Years",No,2000
NCT04423861,Not yet recruiting,July 2020,August 2020,covid19,"Randomized,Parallel Assignment,Patients will be randomized to receive either nitazoxanide or placebo (1:1),Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04463472,"Active, not recruiting","June 29, 2020","July 31, 2021",COVID-19,"Non-Randomized,Sequential Assignment,Prevention,None (Open Label)","gender:All,Min Age:20 Years,Max Age:65 Years",No,30
NCT04368897,Recruiting,"May 1, 2020","December 1, 2020","SARS-CoV 2,COVID,COVID-19,Androgenetic Alopecia,Androgen Receptor Abnormal,Androgen Deficiency","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:Male,Min Age:18 Years,Max Age:N/A",No,200
NCT04531618,Recruiting,"August 13, 2020",December 2021,"Child Development,Mother-Infant Interaction,COVID-19","Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:N/A,Max Age:72 Hours",No,280
NCT04363632,Completed,"April 2, 2020","June 30, 2020","Sars-CoV2,Cancer","Cohort,Other","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1231
NCT04355676,Not yet recruiting,"April 30, 2020","August 30, 2020",Coronavirus Infection,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04437706,Not yet recruiting,"October 1, 2020","June 30, 2021","COVID-19,SARS-CoV 2","Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04302519,Not yet recruiting,"March 5, 2020","July 30, 2021",COVID-19,"N/A,Single Group Assignment,Dental pulp mesenchymal stem cells were injected intravenously,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,24
NCT04397471,Not yet recruiting,May 2020,December 2021,Healthy Volunteers for Bone Marrow Donation,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:40 Years",No,10
NCT04361552,Withdrawn,"April 7, 2020","June 2, 2020","Cerebrovascular Accident,Chronic Obstructive Pulmonary Disease,Chronic Renal Failure,Coronary Artery Disease,Diabetes Mellitus,Malignant Neoplasm,SARS Coronavirus 2 Infection","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04465513,Not yet recruiting,"August 31, 2020","August 31, 2021","Asthma; Eosinophilic,COVID,Covid-19","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,100
NCT04462393,Completed,"March 6, 2020","May 6, 2020","COVID-19,Critical Illness","Cohort,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1563
NCT04255017,Recruiting,"February 1, 2020","July 1, 2020",2019-nCoV,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04575064,"Active, not recruiting","June 29, 2020",November 2022,"SARS-CoV-2 Infection,COVID-19,Moderate and Severe COVID-19","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04470531,Recruiting,"July 12, 2020","January 30, 2021","Covid19,Severe COVID-19 Patients","Randomized,Parallel Assignment,Arm A :control group will receive standard treatment, Arm B: experimental group will receive standard care and oral co-triamoxazole,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:70 Years",No,94
NCT04392453,Not yet recruiting,May 2020,December 2020,Stroke,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:85 Years",No,40
NCT04374513,Recruiting,"May 2, 2020",April 2021,Covid19,"Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,50
NCT04399681,Recruiting,"May 10, 2020","September 10, 2020","COVID,Pneumonia, Viral","N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04540393,Not yet recruiting,"August 26, 2020","March 5, 2021",COVID-19,"N/A,Single Group Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04384965,Recruiting,"May 12, 2020","November 1, 2022",Major Depressive Disorder,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04379986,Not yet recruiting,"May 1, 2020","June 1, 2020",Blood Pressure,"Non-Randomized,Single Group Assignment,Device Feasibility,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04425460,Not yet recruiting,June 2020,September 2020,COVID-19,"Randomized,Parallel Assignment,This is a multi-center, randomized, double-blind, placebo-controlled (1:1) clinical study to explore the efficacy and safety of Favipiravir,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:75 Years",No,256
NCT04385121,Recruiting,"April 16, 2020",March 2021,"Covid-19,Stress Disorders, Post-Traumatic,Anxiety,Depression","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04568551,Recruiting,"October 1, 2020","July 31, 2021",Anxiety State,"Cohort,Prospective","sampling_method:Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,300
NCT04570189,Not yet recruiting,September 2020,January 2021,COVID-19,"Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,40
NCT04502342,Enrolling by invitation,"June 1, 2020","September 30, 2020",Covid19,"Randomized,Parallel Assignment,Eligible consenting symptomatic patients with COVID-19 confirmed by a positive Polymerase Chain Reaction test were subjected to the 10 days of treatment allocated to each of the 3 arms of the trial. Virological clearance is assessed on days 3, 6 and 14. Side effects and the onset of COVID symptoms are evaluated throughout the trial period. Clinical, paraclinical and laboratory examinations are occasionally provided. The data are statiscally processed.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,30
NCT04416100,Recruiting,"April 29, 2020","April 28, 2022","Covid-19,Pulmonary Fibrosis","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,130
NCT04558437,Recruiting,"June 12, 2020","December 31, 2020","Post Traumatic Stress Disorder (PTSD),Anxiety,Depression,Epidemic Disease,COVID19","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,20000
NCT04547218,Recruiting,"June 22, 2020","December 31, 2020","Age Problem,Surgery,Depression, Anxiety","Case-Only,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:65 Years,Max Age:N/A",No,150
NCT04380935,Recruiting,"May 18, 2020","October 31, 2020","COVID,Acute Respiratory Distress Syndrome","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04561219,"Active, not recruiting","April 19, 2020","October 2, 2020","Covid19,Corona Virus Infection,Pneumonia, Viral","Randomized,Parallel Assignment,Hospitalized patients with clinical signs of COVID-19, and either chest tomography scans suggestive of COVID-19 or confirmed by RT-PCR molecular tests, will be randomly divided into 2 groups: experimental and control groups.
Experimental group: 250 hospitalized patients diagnosed with COVID-19 derived pneumonia will receive nitazoxanide 500mg 8/8 hs for 5 days. Control group: 250 hospitalized patients diagnosed with COVID-19 derived pneumonia will receive placebo 8/8 hs for 5 days.,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Patients were randomly allocated into one of the two groups: A or B. Patients received labelled medication: A or B, by the pharmacist. Patients received an identification number, so care providers, outcomes assessors and investigators did not know anything regarding the patients' groups.","gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT02735707,Recruiting,"April 11, 2016",December 2023,"Community-acquired Pneumonia, Influenza, COVID-19","Randomized,Factorial Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,7100
NCT04536363,Not yet recruiting,"October 1, 2020","March 1, 2021",Covid19,"Randomized,Parallel Assignment,Study type: Open randomized clinical trial. Study phase: Phase II Design: Experimental in parallel Two management groups Intermediate analysis will be carried out when completing 20%, 40%, 60% and 80% of the planned sample. All adjusted statistical analysis will be carried out conditionally, predicting the effect of the stratification of the randomization process.
The statistical analysis will be carried out in accordance with the principle of ""intention to treat"",Treatment,None (Open Label),There are no masking techniques in assigning treatment to patients, as this is an open study. Nor is any procedure for urgently opening emergency codes applicable. The statistical analysis will be carried out without the epidemiologist in charge knowing or being able to identify the group of origin of the patients (control / intervention). To guarantee this, the data of the patients will be reported to the epidemiologist without any identification data and through a code whose sole knowledge at the time of delivery will be the responsibility of the principal investigator. Interim comparisons and analysis will be carried out for mortality and adverse events in the following follow-up stages according to the number of patients achieved: 20%, 40%, 60%, 80% and final.","gender:All,Min Age:18 Years,Max Age:N/A",No,284
NCT04438941,Recruiting,"March 25, 2020","June 20, 2020",Sars-CoV2,"Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04374656,Recruiting,"May 18, 2020",May 2021,"Conjunctivitis,SARS-CoV-2,COVID-19,Ocular Infection, Viral,Ocular Inflammation","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04383470,Recruiting,"April 26, 2020",June 2022,"Mental Health Wellness 1,Pandemic","Ecologic or Community,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:6 Years,Max Age:N/A",No,100000
NCT04384588,Recruiting,"April 7, 2020","April 6, 2021","COVID-19 Infection,Cancer Patients,General Population","Non-Randomized,Parallel Assignment,Multicenter, non-randomized, 4 arms,Treatment,None (Open Label)","gender:All,Min Age:15 Years,Max Age:N/A",No,100
NCT04503434,Completed,"May 15, 2020","June 6, 2020","Patient Preference,COVID-19","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,517
NCT04542434,Not yet recruiting,"November 1, 2020","May 1, 2021",Covid19,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,148
NCT04371432,Recruiting,"October 12, 2020","June 1, 2025","COVID-19,Coronavirus 2019","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:3 Years,Max Age:N/A",No,2500
NCT04462367,Not yet recruiting,"July 1, 2020","December 20, 2022","COVID19,Coronavirus Infection,Pregnancy Disease,Severe Acute Respiratory Syndrome","Cohort,Other","sampling_method:Non-Probability Sample,gender:Female,Min Age:N/A,Max Age:N/A",No,180
NCT04345887,Not yet recruiting,"April 21, 2020","October 21, 2020","Respiratory Distress Syndrome, Adult","Randomized,Parallel Assignment,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04341714,Recruiting,"March 16, 2020","June 15, 2020","Efficacy, Self,Satisfaction, Patient,Telemedicine","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,450
NCT04378257,Not yet recruiting,"June 1, 2020","October 20, 2020","Depressive Symptoms,Generalized Anxiety","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,70
NCT04393558,Recruiting,"April 20, 2020","December 31, 2022","COVID-19,Healthy Control","Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:95 Years",No,100
NCT03331445,Recruiting,"October 24, 2017","March 31, 2021","Respiratory Tract Infections,Corona Virus Infection","Sequential Assignment,Open label safety study (COVID-19 Sub-study),Treatment,None (Open Label)","gender:All,Min Age:19 Years,Max Age:N/A",No,20
NCT04348227,"Active, not recruiting","January 1, 2019","February 4, 2021",Ventilator Associated Pneumonia,"Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,120
NCT04445233,Recruiting,"April 29, 2020",December 2020,COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:1 Year,Max Age:N/A",No,400
NCT04516746,Not yet recruiting,"August 17, 2020","October 5, 2022","COVID-19,SARS-CoV-2","Randomized,Parallel Assignment,Participants are assigned to one of two or more groups in parallel for the duration of the study.,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Double Blind: two or more parties are unaware of the intervention assignment.","gender:All,Min Age:18 Years,Max Age:N/A",No,30000
NCT04411667,Recruiting,"April 28, 2020","November 30, 2020",Sars-CoV2,"Randomized,Parallel Assignment,Subjects will be randomized into one of two groups: Standard of Care plus IVIG or Standard of Care.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04575532,Enrolling by invitation,"October 5, 2020","January 22, 2021",Covid19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04477473,Recruiting,"June 30, 2020","August 31, 2020","COVID-19 Pandemic,Vulnerable Subjects,Long-term Non-invasive Ventilation","Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,100
NCT04379531,Completed,"April 25, 2020","May 22, 2020","Pneumonia,Coronavirus Infection","Non-Randomized,Crossover Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,230
NCT04568356,Completed,"April 24, 2020","September 24, 2020",SARS CoV-2,"N/A,Single Group Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04501172,Completed,"June 25, 2020","August 14, 2020",Covid19,"Other,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:85 Years",No,1214
NCT04355728,"Active, not recruiting","April 25, 2020","December 31, 2020","Corona Virus Infection,ARDS,ARDS, Human,Acute Respiratory Distress Syndrome,COVID-19","Randomized,Parallel Assignment,The trial has two groups, each with 12 subjects (n=24). All eligible subjects will be randomized to either the treatment group or standard of care, and randomization will be stratified by ARDS severity.,Treatment,Triple (Participant, Care Provider, Investigator),Double-Blinding Trial","gender:All,Min Age:18 Years,Max Age:N/A",No,24
NCT04526405,Recruiting,"July 14, 2020","October 30, 2020","Thalassemia Major,Covid19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,81
NCT04359329,Recruiting,"April 20, 2020","November 15, 2020",COVID,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,110
NCT04490486,Not yet recruiting,"March 1, 2021","June 1, 2024","COVID-19,Acute Respiratory Distress Syndrome,Corona Virus Infection","Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,21
NCT04373824,Recruiting,"April 25, 2020","July 25, 2020",COVID,"Non-Randomized,Crossover Assignment,25 subjects in each Arm,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,50
NCT04444986,Completed,"June 5, 2020","June 13, 2020",Bioequivalence,"Randomized,Crossover Assignment,Other,None (Open Label)","gender:Male,Min Age:18 Years,Max Age:40 Years",No,30
NCT04456049,Not yet recruiting,July 2020,December 2021,COVID-19 Infection,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:Male,Min Age:50 Years,Max Age:N/A",No,90
NCT04524507,Recruiting,"August 27, 2020",May 2021,COVID-19,"Randomized,Parallel Assignment,This study has 2 treatment arms and participants will be assigned/randomized to one arm:
CCP1 - CCP tested for the presence of anti-SARS-CoV-2 antibodies and assigned high-titer
CCP2 - CCP tested for the presence of anti-SARS-CoV-2 antibodies and assigned standard-titer,Treatment,Double (Participant, Investigator),This study is double-blinded so neither the participant nor the study team/investigators will know which plasma treatment (CCP1 or CCP2) that the participant is receiving.","gender:All,Min Age:18 Years,Max Age:99 Years",No,56
NCT04418505,Recruiting,"September 2, 2020","March 1, 2021",COVID-19,"Randomized,Parallel Assignment,Prospective, randomized trial,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,280
NCT04350684,Enrolling by invitation,"April 15, 2020","April 24, 2020",COVID-19,"Randomized,Parallel Assignment,The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.,Treatment,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04525287,Recruiting,"February 20, 2020","August 20, 2020","Coronavirus Infection,COVID19","Case-Crossover,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1000
NCT04453384,Recruiting,"September 1, 2020",December 2021,SARS Virus,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:85 Years",No,368
NCT04321421,Completed,"March 17, 2020","May 7, 2020",COVID-19,"N/A,Single Group Assignment,Longitudinal assessment of COVID-19 patients treated with hyperimmune plasma,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,49
NCT04357782,"Active, not recruiting","April 16, 2020","October 15, 2020","COVID-19,Hypoxia","Non-Randomized,Single Group Assignment,Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:99 Years",No,20
NCT04359914,Recruiting,"April 15, 2020","April 1, 2021","Critical Illness,COVID-19,Central Nervous System Injury,Delirium,Encephalopathy","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,80
NCT04378686,Recruiting,"April 23, 2020","May 1, 2022","SARS-CoV 2,End Stage Renal Failure on Dialysis","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04510519,Not yet recruiting,"September 1, 2020","June 30, 2021","Major Depressive Disorder,Generalized Anxiety","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,50
NCT04364828,Not yet recruiting,April 2020,August 2021,COVID-19,"Non-Randomized,Sequential Assignment,Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04343898,"Active, not recruiting","April 1, 2020","August 1, 2022",Coronavirus Infection,"Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,5253
NCT04367792,"Active, not recruiting","April 23, 2020",March 2021,COVID-19,"Case-Control,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04362332,Terminated,"April 14, 2020","June 8, 2020",COVID-19,"Randomized,Parallel Assignment,Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
Supportive care only.,Treatment,None (Open Label),cluster randomized design","gender:All,Min Age:18 Years,Max Age:110 Years",No,25
NCT04451174,Recruiting,"June 23, 2020","September 30, 2020",COVID-19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:90 Years",No,184
NCT04394390,Enrolling by invitation,"May 1, 2020","June 30, 2020",COVID,"Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04303507,Recruiting,"April 29, 2020",April 2021,"COVID19,Coronavirus,Acute Respiratory Illnesses","Randomized,Parallel Assignment,Prevention,Double (Participant, Investigator)","gender:All,Min Age:16 Years,Max Age:N/A",No,40000
NCT04435119,Completed,"March 15, 2020","May 15, 2020",Coronavirus,"Cohort,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:70 Years,Max Age:N/A",No,96
NCT04366934,Recruiting,"May 4, 2020","September 15, 2022","Coronavirus Infection,Severe Acute Respiratory Syndrome,Sars-CoV2","Case-Control,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,24
NCT04354870,Completed,"April 3, 2020","October 1, 2020",COVID-19,"Non-Randomized,Parallel Assignment,Total number of participant: 350 (Group A and B)
Group A: projected 300 (HCW choose to be provided HCQ)
Group B: projected 50 (HCW choose not to be provided HCQ),Treatment,None (Open Label),Open Label","gender:All,Min Age:18 Years,Max Age:N/A",No,130
NCT04339712,Recruiting,"April 2, 2020","April 1, 2022","COVID-19,Virus Diseases,Macrophage Activation Syndrome,Corona Virus Infection","Non-Randomized,Factorial Assignment,Treatment with tocilizumab or anakinra,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04367142,Not yet recruiting,September 2020,December 2020,Sars-CoV2,"Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,200
NCT04442230,Recruiting,"September 29, 2020",February 2021,Coronavirus Infection,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator),Double-Blind","gender:All,Min Age:18 Years,Max Age:N/A",No,96
NCT04413877,Not yet recruiting,October 2020,November 2021,"Frailty Syndrome,COVID-19,Healthy Aging,Old Age; Debility","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:65 Years,Max Age:N/A",No,600
NCT04559113,Recruiting,"May 1, 2020","October 30, 2020","SARS-CoV Infection,SARS (Severe Acute Respiratory Syndrome)","N/A,Single Group Assignment,quasi-experimental,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,200
NCT04379284,Recruiting,"May 8, 2020","July 31, 2021",COVID19,"Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:45 Years",No,100
NCT04384549,Recruiting,"May 20, 2020","February 20, 2021","Infection,Viral, Agent as Cause of Disease Classified Elsewhere","Randomized,Parallel Assignment,Prevention,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,1120
NCT04546737,Recruiting,"September 8, 2020",May 2022,"Covid19,Neurological Manifestations,Brain Damage","Non-Randomized,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04335123,Recruiting,"March 25, 2020",October 2020,COVID-19,"N/A,Single Group Assignment,50 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Patients and/or surrogate decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group.We will also collect medical information relating to safety criteria on historical controls treated at the University of Kansas Hospital in the 30 days prior to the study start date (3/25/2020) and during the study period.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04370821,Recruiting,"May 9, 2020","April 27, 2040","Occupational Exposure to SARS-CoV-2,COVID-19","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,20000
NCT04474249,Recruiting,"June 25, 2020",December 2022,"COVID19,ARDS,AKI,Circulatory Failure,Coagulation Disorder,Inflammatory Response","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04342689,Recruiting,"June 3, 2020","June 1, 2021",COVID-19,"Randomized,Parallel Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:19 Years,Max Age:N/A",No,1500
NCT04368312,Not yet recruiting,"May 6, 2020","May 30, 2020","Psychological Distress,Quality of Life","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04409951,Not yet recruiting,November 2020,September 2021,"Event, Life Change","Case-Crossover,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:16 Years,Max Age:40 Years",No,100
NCT04492891,Not yet recruiting,"August 20, 2020","August 20, 2025",SARS (Disease),"Randomized,Parallel Assignment,Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no CSA + SOC.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:90 Years",No,75
NCT04452565,Recruiting,"October 15, 2020","February 15, 2021","Coronavirus Infection,Severe Acute Respiratory Infection,Severe Acute Respiratory Syndrome Coronavirus 2","Randomized,Parallel Assignment,Prevention,Triple (Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:80 Years",No,525
NCT04483830,Completed,"June 5, 2020","September 7, 2020",Covid19,"Randomized,Parallel Assignment,prospective, single centre, randomized, placebo-control trial,Treatment,Single (Participant),placebo control","gender:All,Min Age:40 Years,Max Age:80 Years",No,243
NCT04254874,Recruiting,"February 1, 2020","July 1, 2020",2019-nCoV,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04403477,Recruiting,"May 20, 2020","October 30, 2020","Covid19,Convalescence","Randomized,Parallel Assignment,Arm-A: Standard supportive treatment; Arm-B: Standard supportive treatment + CP 200 ml; Arm C: Standard supportive treatment + CP 400 ml,Treatment,None (Open Label)","gender:All,Min Age:16 Years,Max Age:N/A",No,20
NCT04409574,Not yet recruiting,June 2020,June 2021,"Infection, Coronavirus","Case-Only,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:50 Years",No,31
NCT04383483,Recruiting,"June 15, 2020","August 31, 2020",Coronavirus as the Cause of Diseases Classified Elsewhere,"Case-Only,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,100
NCT04460664,Enrolling by invitation,"August 14, 2020","February 15, 2021","COVID,Disseminated Intravascular Coagulation,Coagulation Disorder","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04427878,Not yet recruiting,"July 1, 2020","July 9, 2021",Covid-19 Patients,"N/A,Single Group Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,5
NCT04361565,Enrolling by invitation,"March 20, 2020","May 31, 2020",COVID-19 by SARS-CoV-2 Infection,"Case-Only,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,50
NCT04457817,Not yet recruiting,September 2020,September 2021,COVID,"Randomized,Parallel Assignment,COVID-19 patients who require 2 liters of oxygen by nasal cannula (to maintain SpO2 >90%), will be eligible. Study participants will be randomized into standard of care and study patient cohorts. Both cohorts will receive standard monitoring and therapy. Patients in the study cohort will also be monitored with a CipherOx CR T1 tablet in a continuous manner to determine if maintaining CRI vales between 0.9-0.7 will: 1) help guide IV fluid (e.g. crystalloid, colloids, blood products) and medication therapy (e.g. diuretics); 2) allows earlier identification of patients who are poorly compensating and will require ICU level care; 3) reduces acute kidney injury (AKI) and/or need for continuous renal replacement therapy (CRRT); and 4) improves clinical outcomes.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:70 Years",No,100
NCT04511962,Not yet recruiting,"August 12, 2020","January 20, 2022",Pulmonary Disease,"Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04463264,Recruiting,"June 26, 2020","October 26, 2020",COVID-19,"Randomized,Parallel Assignment,Randomized. Nitazoxanide : Placebo (2:1), parallel-group study,Treatment,Single (Participant),Simple blind design","gender:All,Min Age:18 Years,Max Age:59 Years",No,135
NCT04444700,Recruiting,"July 4, 2020","December 31, 2020","COVID,Coronavirus Infection,Severe Acute Respiratory Syndrome,Thromboembolism, Venous,Anticoagulants and Bleeding Disorders","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,462
NCT04443699,Not yet recruiting,"June 22, 2020","July 13, 2020",Mental Well-being,"Other,Prospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04430374,Recruiting,"June 2, 2020","December 31, 2020",Cardiovascular Diseases,"Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,100
NCT04498325,Not yet recruiting,"October 31, 2020","July 31, 2021","COVID-19,SARS-CoV-2","Randomized,Parallel Assignment,The study will open as a phase I study to test three different dose levels of NT-I7. Once a safe tolerated dose is established, the pilot portion of the study will be activated wherein participants will be randomized on a 1:1 basis to receive a single injection of NT-I7 (at the safe tolerated dose) or placebo.,Treatment,Triple (Participant, Care Provider, Investigator),The clinicians, participants, and clinical research coordinators will be blinded","gender:All,Min Age:18 Years,Max Age:N/A",No,42
NCT04385212,Completed,"March 13, 2020","April 14, 2020","Coronavirus Infection,Sars-CoV2,Elderly Infection,Old Age; Debility","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:65 Years,Max Age:N/A",No,230
NCT04382846,Not yet recruiting,"May 8, 2020","December 1, 2030","COVID,Corona Virus Infection","Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04405999,Completed,"May 14, 2020","August 31, 2020",Increased Risk of SARS-CoV-2 Infection,"Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04405869,Recruiting,"April 29, 2020",April 2021,Pulmonary Thromboembolism,"Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04549350,Completed,"May 19, 2020","September 5, 2020",Sleep Quality,"Other,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:25 Years,Max Age:60 Years",No,217
NCT04401579,"Active, not recruiting","May 8, 2020","August 1, 2023",COVID-19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:99 Years",No,1034
NCT04492514,Recruiting,"May 20, 2020","May 31, 2021","COVID 19,SARS-CoV 2,Pneumonia","Randomized,Factorial Assignment,Factorial Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Quadruple (Particiapnt, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04268537,Not yet recruiting,"February 10, 2020","October 31, 2020","2019 nCoV, PD-1","Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,120
NCT04379544,Recruiting,"April 23, 2020",December 2020,"Coronavirus,Respiratory Failure","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,105
NCT04551378,Recruiting,"July 13, 2020","December 31, 2021","COVID-19 Infection,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:39 Years",No,600
NCT04376684,Recruiting,"May 28, 2020","December 21, 2020",Severe Acute Respiratory Syndrome,"Randomized,Parallel Assignment,Participants will be randomized to receive either a blinded IV infusion of otilimab or placebo, in addition to standard of care.,Treatment,Double (Participant, Investigator),This is a double-blind study.","gender:All,Min Age:18 Years,Max Age:79 Years",No,800
NCT04373382,Recruiting,"July 27, 2020",February 2022,Burnout,"Randomized,Crossover Assignment,Hospital staff will receive support from Peer Resilience Champions, whose activities will, in part, be modelled on the role that psychiatrists acting as support coaches have played in during the acute phase of the pandemic. These include support, identification of needs, education, advocacy and resource navigation. In doing so, they follow evidence-based principles and guidelines.
A randomized cluster stepped wedge design will be used, with five clusters of clinical units and departments constructed in order to approximate the following goals: similar number of staff, comparable COVID-19 exposure, similar mix of staff by discipline and gender, number of clusters small enough to allow for the PRC intervention to be provided with at least six months of implementation within the two-year study after cross-over occurs. (Two arms).
The Enriched survey intervention will be a randomized controlled trial design with equal allocation (1:1) to both the express and enriched surveys. (Two arms).,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04401046,Recruiting,"May 20, 2020","October 30, 2020",Cancer,"N/A,Single Group Assignment,Health Services Research,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,4000
NCT04479280,Completed,"July 20, 2020","August 16, 2020",Coagulation Disorder,"Case-Control,Prospective","sampling_method:Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,70
NCT04471649,Recruiting,"June 15, 2020",November 2020,COVID,"Case-Control,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04407195,"Active, not recruiting","June 1, 2020","June 1, 2021","COVID-19,Mental Health Disorder","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2000
NCT04337359,Available,N/A,N/A,N/A,N/A,"gender:All,Min Age:6 Years,Max Age:90 Years",No,N/A
NCT04537585,Not yet recruiting,November 2020,December 2022,Covid19,"Randomized,Parallel Assignment,Investigators couldn't agree more to wait without to know how to treat their patients better and want to learn about therapeutic nutrition approach called TOMEKA versus prophylaxis dosing of antioxidant as Vernonia amygdalina as a study. Investigators are learning about that here in September, why wasn't that done in April? Investigators would submit to follow a parallel group, just speaking as researchers about randomisation, one of the reasons difficult to reach that elaborate study design is sometimes bureaucracy is just daunting.,Prevention,None (Open Label),The fact that you can't really study anything unless there's funding for it because the insurance companies and the hospitals are not going to pay for things on a trial unless there is funding. Then you add to that there is no funding for food as medicine, and things as herbs like Vernonia amygdalina that improve the quality of life in COVID-19 patients and they are not pharmaceutical. Those are sort of the real-world complaints, investigators would say, on the front lines to follow participants in parallel group i.e. compare the ones who take herbs as medicine for their survival and other who use others means to fight COVID-19 symptoms.","gender:All,Min Age:15 Years,Max Age:65 Years",No,2000
NCT04488549,Completed,"May 20, 2020","June 10, 2020","Colo-rectal Cancer,Colon Cancer,Rectal Cancer,Oncology,Surgery","Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,1051
NCT04351542,Completed,"March 6, 2020","April 12, 2020",Flu Like Illness,"Non-Randomized,Parallel Assignment,Supportive Care,Single (Care Provider),Ayurveda care provide was blinded","gender:All,Min Age:18 Years,Max Age:60 Years",No,32
NCT04516850,Not yet recruiting,"September 1, 2020","August 31, 2021",Covid19,"Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04409873,Not yet recruiting,"October 1, 2020","August 31, 2021","COVID-19,SARS-CoV 2,Severe Acute Respiratory Syndrome Coronavirus 2,Virus Disease,Coronavirus Infections,Pharyngeal Diseases","Randomized,Parallel Assignment,A blinded randomized controlled parallel group design trial,Supportive Care,Double (Participant, Outcomes Assessor),Study participants will be blinded to the solutions to the extent possible (i.e., similar packages with identification number bar codes).
The lab technician who evaluates the SARS-CoV-2 load in samples will be blinded to the solutions and study groups.","gender:All,Min Age:18 Years,Max Age:N/A",No,150
NCT04433039,Completed,"May 22, 2020","June 14, 2020",COVID,"Case-Crossover,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:4 Years,Max Age:80 Years",No,130
NCT04441424,Completed,"April 3, 2020","June 1, 2020",IMMUNOTHERAPY,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,49
NCT04548934,Not yet recruiting,"September 13, 2020","December 31, 2020","Cardiopulmonary Resuscitation,Personal Protective Equipment","Randomized,Crossover Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:60 Years",No,28
NCT04439825,Not yet recruiting,"July 15, 2020","October 15, 2020",Mood,"Randomized,Crossover Assignment,Treatment,Single (Participant)","gender:All,Min Age:10 Years,Max Age:75 Years",No,45
NCT04334954,Recruiting,"August 26, 2020","March 31, 2022",SARS-COV2 Virus,"Case-Only,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,15000
NCT04448054,Recruiting,"May 20, 2020","November 20, 2021","Estimate, With the Contribution of Optimized MRI, the Prevalence of Neurological and Neurovascular Manifestations on Imaging in the Event of SARS-CoV-2","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04025580,Recruiting,"October 2, 2019","December 31, 2025","Healthy Volunteer,COVID-19","N/A,Single Group Assignment,Basic Science,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04335630,Recruiting,"March 30, 2020",March 2022,"Cardiovascular Diseases,COVID","Case-Control,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,500
NCT04372004,Recruiting,"May 8, 2020",June 2021,COVID-19,"Non-Randomized,Parallel Assignment,Each subject will be tested using 3 different samples on two testing platforms (serology and viral-RNA detection),Diagnostic,None (Open Label)","gender:All,Min Age:18 Years,Max Age:85 Years",No,100
NCT04362319,Completed,"May 15, 2020","May 31, 2020","Burnout, Professional,Depression,Medical Errors,Covid-19","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,85
NCT04434014,Recruiting,"June 8, 2020","June 28, 2020","Diet, Healthy","Ecologic or Community,Prospective","sampling_method:Probability Sample,gender:All,Min Age:20 Years,Max Age:60 Years",No,300
NCT04527614,Not yet recruiting,"September 1, 2020","May 30, 2021","Influenza, Human,SARS Virus,COVID-19,Espiratory Tract Infections","Parallel Assignment,Diagnostic,Double (Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,2000
NCT04299152,Not yet recruiting,"May 10, 2020","November 10, 2020",Severe Acute Respiratory Syndrome (SARS) Pneumonia,"Randomized,Parallel Assignment,This is a prospective, two-arm, partially masked, single center clinical study to assess the safety, feasibility, and efficacy of SCE therapy for the treatment of patients with SARS-CoV-2.,Treatment,Single (Care Provider)","gender:All,Min Age:18 Years,Max Age:60 Years",No,20
NCT04465552,Recruiting,"July 10, 2020",December 2020,Coronavirus Infections,"Case-Control,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,750
NCT04459533,Completed,"June 1, 2020","June 1, 2020","Neuromuscular Blockade,Human Characteristics,Complication of Medical Care,Intensive Care Unit Acquired Weakness","Case-Control,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,250
NCT04327206,Recruiting,"March 30, 2020","March 30, 2022","Coronavirus Disease 2019 (COVID-19),Respiratory Illness,Corona Virus Infection,COVID-19","Randomized,Parallel Assignment,Phase III, two group, multicentre, randomised controlled trial,Prevention,Double (Participant, Outcomes Assessor),The control group will receive a placebo of 0.9% sodium chloride (NaCl). Members of the research team doing the follow-up of participants and analysis will be blinded to the group allocation (by the removal of this variable and all other variables related to BCG from the dataset) until the formal detailed statistical analysis plan is confirmed and signed by all investigators and all data cleaning/preparation is complete.","gender:All,Min Age:18 Years,Max Age:N/A",No,10078
NCT04434118,Enrolling by invitation,"March 20, 2020","December 30, 2020","Rheumatoid Arthritis,COVID","Case-Control,Retrospective","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:60 Years",No,600
NCT04354155,Recruiting,"June 2, 2020","October 15, 2022","Infection Viral,Thromboses, Venous,COVID-19","N/A,Single Group Assignment,Prevention,None (Open Label)","gender:All,Min Age:N/A,Max Age:18 Years",No,38
NCT04412265,Recruiting,"March 1, 2020","March 1, 2021",Covid19,"Case-Only,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04349098,Recruiting,"April 17, 2020","August 31, 2020",Coronavirus Infection,"Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:N/A",No,230
NCT04319315,Recruiting,"March 11, 2020","April 16, 2020",COVID-19,"Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:25 Years,Max Age:65 Years",No,400
NCT04344249,Recruiting,"April 10, 2020","September 1, 2021","IBD,COVID","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,850
NCT04528888,Not yet recruiting,"September 1, 2020","July 30, 2021","Covid19,SARS-CoV Infection,Pneumonia, Viral,Coagulopathy","Randomized,Parallel Assignment,The study is designed as a multicenter, national, interventional, randomized, investigator sponsored, three arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned to one of the three treatment groups in a ratio 1:1:1. A block randomisation will be used with variable block sizes (block size 4-6-8), stratified by centre. Central randomisation will be performed using a secure, web-based, randomisation system. The allocation sequence will be generated by the study statistician using computer generated random numbers.,Treatment,None (Open Label),The study in conceived as open-label: the patients and all the health-care personnel will be aware of the assigned group.","gender:All,Min Age:18 Years,Max Age:N/A",No,210
NCT04315896,"Active, not recruiting","April 14, 2020","August 15, 2020","COVID-19,Severe Acute Respiratory Syndrome","Randomized,Parallel Assignment,Double blinded, randomized controlled trial,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Clinical practitioners and data analysts will remain blinded all through the study. Blinding will end in case the attending physician considers the patient should abandon the study or some of the exclusion/elimination criteria apply.","gender:All,Min Age:18 Years,Max Age:80 Years",No,500
NCT04480138,Recruiting,"August 11, 2020","January 30, 2021",Covid19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,40
NCT04462848,Not yet recruiting,August 2020,December 2024,Corona Virus Infection,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:1 Month,Max Age:17 Years",No,30
NCT04394104,Not yet recruiting,"May 27, 2020","May 31, 2020",Health Behavior,"Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1000
NCT04512079,Not yet recruiting,September 2020,June 2021,"COVID-19,SARS-CoV-2","Randomized,Parallel Assignment,Study participants will be randomized in a 1:1:1 fashion to 1 of 3 arms:
Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl <30 mL/min)
Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl <30 mL/min)
Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL),Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",N/A,3600
NCT04354792,Completed,"May 1, 2020","June 10, 2020",Immunologic Activity Alteration,"Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:25 Years,Max Age:60 Years",No,500
NCT04510402,Not yet recruiting,August 2020,April 2021,"Covid19,Povidone Iodine Adverse Reaction","Non-Randomized,Parallel Assignment,Fifty healthy volunteers to use single application or double application of PVP-I nasal swabs and assess for safety and tolerability,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:70 Years",No,50
NCT04366752,Recruiting,"April 22, 2020","September 22, 2020","COVID-19,Pneumonia,ARDS,Hemostasis,Coagulation","Case-Only,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04566276,Not yet recruiting,January 2021,June 2021,"COVID-19 Vaccine,Safety Issues","Non-Randomized,Sequential Assignment,Healthy adults (age 18 to 55 years) and elderlies (age 65 to 75 years) will be enrolled sequentially in an ascending dose fashion (10 µg, 25 µg, 50 µg, and 100 µg).,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:75 Years",No,96
NCT04333550,Recruiting,April 2020,March 2021,COVID-19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:3 Years,Max Age:99 Years",No,50
NCT04387643,Completed,"March 1, 2020","April 2, 2020",Covid-19,"Other,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:60 Years",No,52
NCT04482205,Completed,"March 16, 2020","May 31, 2020",Economic Burden,"Other,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,840
NCT04547634,Enrolling by invitation,"July 1, 2020",December 2020,"Cancer Metastatic,Cancer,Survivorship","Randomized,Crossover Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:65 Years",No,30
NCT04492202,Not yet recruiting,"August 1, 2020","December 10, 2020","COVID,Knowledge, Attitudes, Practice","Other,Other","sampling_method:Probability Sample,gender:All,Min Age:22 Years,Max Age:75 Years",No,200
NCT04357106,Recruiting,"April 13, 2020",August 2020,COVID-19,"N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,10
NCT04325867,Recruiting,"March 31, 2020","October 1, 2020","Angina Pectoris,Acute Coronary Syndrome,Coronary Syndrome,Coronary Artery Disease,Angioplasty,Stent Restenosis,Hypertension,Heart Failure, Systolic,Depression, Anxiety,Covid-19,Isolation, Social","N/A,Single Group Assignment,All patients with severe cardiovascular disease benefit from this project,Health Services Research,None (Open Label)","gender:All,Min Age:N/A,Max Age:N/A",No,200
NCT04427865,Not yet recruiting,July 2020,November 2020,COVID-19,"Randomized,Parallel Assignment,Prevention,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,200
NCT04367402,Recruiting,"March 30, 2020",September 2020,COVID-19,"Case-Control,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,600
NCT04407390,Recruiting,"June 1, 2020","May 1, 2022",COVID,"Randomized,Parallel Assignment,Randomized double-blind case-control trial,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:70 Years,Max Age:N/A",No,100
NCT04365608,Recruiting,"March 20, 2020","May 20, 2020","Intubation Complication,Intubation; Difficult or Failed,Cardiac Arrest,Influenza,Safety Issues","Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,90
NCT04548544,Completed,"October 18, 2019","May 20, 2020",Healthy,"Randomized,Parallel Assignment,Basic Science,Single (Participant)","gender:All,Min Age:14 Years,Max Age:18 Years",No,21
NCT04339686,Recruiting,"April 20, 2020",November 2020,The Gold Standard for Current SARS CoV2 Detection is RT-PCR,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:100 Years",No,56000
NCT04322123,"Active, not recruiting","April 1, 2020","August 30, 2020",Coronavirus Infections,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,630
NCT04348877,Not yet recruiting,"April 20, 2020",December 2020,Coronavirus Disease (COVID-19),"N/A,Single Group Assignment,Antibody-Rich Plasma from COVID-19 recovered patients,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:80 Years",No,20
NCT04310228,Recruiting,"March 8, 2020",May 2020,COVID-19,"Randomized,Parallel Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:65 Years",No,150
NCT04357275,Recruiting,"March 13, 2020",March 2022,"Critical Illness,ARDS,Inflammatory Response,COVID-19,Circulatory Shock","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,10000
NCT04314232,Recruiting,"March 18, 2020","December 31, 2021","COVID,Coronavirus Infection","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,200
NCT04488588,Completed,"March 15, 2020","July 1, 2020","Covid19,Coronavirus Disease,SARS-CoV-2","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:36 Years,Max Age:63 Years",No,1064
NCT04412356,Recruiting,"June 4, 2020","February 1, 2021","Covid-19,ARDS,Tracheostomy Complication,Respiratory Insufficiency,Corona Virus Infection","Randomized,Parallel Assignment,Randomized, single blinded, controlled trial,Treatment,Single (Participant),Patients will be blinded to the randomization outcome.","gender:All,Min Age:18 Years,Max Age:N/A",No,180
NCT04564716,Recruiting,"September 28, 2020","April 10, 2021",Covid19,"Randomized,Parallel Assignment,Randomized double-blind placebo-controlled,Prevention,Double (Participant, Investigator),Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:60 Years",No,100
NCT04508777,Enrolling by invitation,"September 9, 2020",March 2021,Covid19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,600
NCT04554979,Completed,"June 1, 2020","July 15, 2020","Covid19,Diarrhea","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,199
NCT04387656,Recruiting,"May 21, 2020","May 31, 2023","Asymptomatic COVID-19 Infection Laboratory-Confirmed,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm,Symptomatic COVID-19 Infection Laboratory-Confirmed","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,2000
NCT04386291,Recruiting,"May 25, 2020","January 30, 2022","Generalized Anxiety,Health Anxiety","Randomized,Parallel Assignment,Participants are randomly assigned to one of three treatment arms: Anxiety Reduction Training (A.R.T.), ART with Kundalini Yoga, ART with Meditation,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:70 Years",No,360
NCT04343963,Recruiting,"April 4, 2020","April 30, 2021","COVID-19,SARS-CoV-2","Randomized,Parallel Assignment,Participants will receive pyridostigmine at a dose of 60 mg / day (or matching placebo), P.O. during a period of up to 14 days, until hospital discharge, death, mechanical ventilation, or increase in the SOFA scale ≥2 points.
The proposed dose is a safe dose according to the experience in myasthenia gravis and healthy people, as well as in at least three clinical studies in people living with HIV.
Participants will be double-blind 1: 1 randomized to receive pyridostigmine or placebo for up to 14 days.,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,436
NCT04523571,Recruiting,"July 28, 2020",August 2021,SARS-CoV-2,"Randomized,Parallel Assignment,Prevention,Triple (Participant, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:85 Years",No,144
NCT04394026,Recruiting,"April 16, 2020","October 1, 2020","Viral Pneumonia,COVID","Cohort,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,500
NCT04385004,Recruiting,"April 27, 2020",July 2020,Acute Respiratory Distress Syndrome,"Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,320
NCT04527211,Not yet recruiting,"September 7, 2020","December 16, 2020","Covid19,Healthcare Worker Patient Transmission","Randomized,Parallel Assignment,It will be performed a randomized, multicenter, triple-masked, placebo-controlled clinical experiment to determine the relative risk of SARS COV-2 infection, seroconversion, and clinically presenting disease.,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Simple randomization will be done with a random number generator and masking will be maintained by concealing the allocation with opaque envelopes. The active medicine as the control will have the same presentation, color and taste, it will be differentiated by a pre-established code from the maker. This will maintain the concealment of patients, caregivers and evaluators. At the central level, only an intervention safety coordinator will know the assignment of each patient in case serious adverse events occur and the concealment needs to be lifted. The outcomes of interest will be obtained from the clinical history of the patients and through direct measurement in the follow-up visits.","gender:All,Min Age:18 Years,Max Age:N/A",No,550
NCT04407117,Completed,"March 23, 2017","April 19, 2020",Appendicitis,"Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,6000000
NCT04386460,Recruiting,"May 11, 2020","May 11, 2021","Nutrition Poor,Infection Viral,Oral Disease","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,100
NCT04347460,Recruiting,"March 27, 2020","August 31, 2020",COVID,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,20
NCT04406194,Completed,"May 14, 2020","June 19, 2020",Bioequivalence,"Randomized,Crossover Assignment,Other,None (Open Label)","gender:Male,Min Age:20 Years,Max Age:40 Years",No,30
NCT04453488,Not yet recruiting,"July 30, 2020",December 2020,"Covid-19,Sars-CoV2","Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,315
NCT04468217,Recruiting,"June 2, 2020","September 25, 2020","COVID,SARS-CoV2,Corona Virus Infection","Case-Control,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:75 Years",No,150
NCT04456153,Recruiting,"July 22, 2020",March 2021,COVID-19,"Randomized,Parallel Assignment,Treatment,Double (Participant, Investigator)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04354779,Completed,"May 11, 2020","September 28, 2020","Severe Acute Respiratory Syndrome Coronavirus 2,SARS-CoV 2,Coronavirus Infection,Covid19","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:15 Years,Max Age:90 Years",No,3301
NCT04501796,Recruiting,August 2020,December 2021,COVID-19,"Randomized,Sequential Assignment,Treatment,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Double-Blind.","gender:All,Min Age:18 Years,Max Age:75 Years",No,30
NCT04560881,Recruiting,"September 16, 2020","December 1, 2021",COVID-19 Virus Infection,"Randomized,Parallel Assignment,Clinical trial conducted in randomized, double-blinded, placebo-controlled design.,Prevention,Triple (Participant, Care Provider, Investigator)","gender:All,Min Age:18 Years,Max Age:85 Years",No,3000
NCT04351568,Recruiting,"April 1, 2020",August 2020,Evaluating the Effect of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics,"Ecologic or Community,Cross-Sectional","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:60 Years",No,874
NCT04329559,Recruiting,"March 30, 2020","June 29, 2021","COVID-19,Liver Cirrhosis","Cohort,Cross-Sectional","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,50
NCT04406558,Recruiting,"May 27, 2020",November 2020,"Psychological Adaptation,Psychology, Social","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:11 Years,Max Age:18 Years",No,400
NCT04569292,Recruiting,"January 1, 2020",August 2021,Covid19,"Case-Only,Other","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,150
NCT04481646,Recruiting,"June 12, 2020",June 2025,Covid19,"Cohort,Prospective","sampling_method:Probability Sample,gender:All,Min Age:16 Years,Max Age:N/A",No,630
NCT04474444,Recruiting,"March 23, 2019","March 23, 2021","Alcohol Use, Unspecified,Substance Use,Intoxication Alcohol,Emergencies,COVID-19 Pandemic,Treatment","Case-Only,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,55000
NCT04411680,Recruiting,"August 18, 2020",March 2021,"COVID-19,Sars-CoV2","Randomized,Parallel Assignment,This Phase 2, randomized, open-label study will enroll approximately 60 patients with COVID-19 associated acute hypoxemia. It is a randomized 2:1 study to evaluate sargramostim treatment plus institutional standard of care compared to institutional standard of care alone.,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,60
NCT04409184,Withdrawn,"August 14, 2020","August 14, 2020","COVID,Sars-CoV2","Cohort,Retrospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,0
NCT04336787,Not yet recruiting,"April 12, 2020","June 10, 2020","Covid-19,Coronavirus Infection,Pregnancy Related","Ecologic or Community,Prospective","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:45 Years",No,100
NCT04414124,Recruiting,"July 2, 2020",December 2020,Mild-to-moderate COVID-19,"Randomized,Parallel Assignment,Other,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,400
NCT04393233,Recruiting,"April 23, 2020","May 23, 2020","Rheumatoid Arthritis,COVID","Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,300
NCT04424134,Recruiting,"May 16, 2020","August 23, 2020",COVID 19,"Randomized,Parallel Assignment,Treatment,Single (Outcomes Assessor)","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04397328,Not yet recruiting,"May 19, 2020","April 30, 2021",COVID-19,"Randomized,Parallel Assignment,Prevention,Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","gender:All,Min Age:40 Years,Max Age:N/A",No,336
NCT04406038,"Active, not recruiting","May 27, 2020","October 28, 2020",COVID19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:18 Years,Max Age:N/A",No,1038
NCT03648372,Recruiting,"October 1, 2018","October 6, 2021","Neoplasms,Lymphoma,Hematologic Neoplasms,Coronavirus Disease","N/A,Single Group Assignment,Treatment,None (Open Label)","gender:All,Min Age:18 Years,Max Age:N/A",No,80
NCT04384731,Recruiting,"May 29, 2020","January 30, 2021","COVID-19,ARDS, Human","Randomized,Parallel Assignment,Treatment,Single (Participant)","gender:All,Min Age:18 Years,Max Age:100 Years",No,20
NCT04368260,Recruiting,"April 24, 2020","July 31, 2020",COVID19,"Non-Randomized,Parallel Assignment,The primary objective of this study is to determine whether the newly designed nasopharyngeal swabs perform acceptably compared to standard swabs.,Other,None (Open Label)","gender:All,Min Age:N/A,Max Age:99 Years",No,40
NCT04351139,Recruiting,"May 6, 2020","November 6, 2020","Gynecologic Cancer,Breast Neoplasm Female,Uterine Neoplasms,Ovarian Neoplasms,Uterine Cervical Neoplasms,Vulvar Neoplasms,Vaginal Neoplasms","Case-Control,Other","sampling_method:Non-Probability Sample,gender:Female,Min Age:18 Years,Max Age:N/A",No,400
NCT04342208,Not yet recruiting,"April 10, 2020","July 1, 2020",Musculoskeletal Pain,"Case-Only,Other","sampling_method:Probability Sample,gender:All,Min Age:18 Years,Max Age:65 Years",No,500
NCT04350099,Not yet recruiting,"April 15, 2020","June 15, 2021",Emotionnal Distress; COVID-19,"Cohort,Prospective","sampling_method:Non-Probability Sample,gender:All,Min Age:N/A,Max Age:N/A",No,200